<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">18082</article-id><article-id pub-id-type="doi">10.7554/eLife.18082</article-id><article-categories><subj-group subj-group-type="heading"><subject>Epidemiology and Global Health</subject></subj-group><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Epidemiology and burden of multidrug-resistant bacterial infection in a developing country</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-58613"><name><surname>Lim</surname><given-names>Cherry</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2555-6980</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib">†</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-58614"><name><surname>Takahashi</surname><given-names>Emi</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-58615"><name><surname>Hongsuwan</surname><given-names>Maliwan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-58616"><name><surname>Wuthiekanun</surname><given-names>Vanaporn</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-58617"><name><surname>Thamlikitkul</surname><given-names>Visanu</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-58618"><name><surname>Hinjoy</surname><given-names>Soawapak</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-35005"><name><surname>Day</surname><given-names>Nicholas PJ</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2309-1171</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-52943"><name><surname>Peacock</surname><given-names>Sharon J</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1718-2782</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-58364"><name><surname>Limmathurotsakul</surname><given-names>Direk</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7240-5320</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution content-type="dept">Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine</institution>, <institution>Mahidol University</institution>, <addr-line><named-content content-type="city">Bangkok</named-content></addr-line>, <country>Thailand</country></aff><aff id="aff2"><label>2</label><institution content-type="dept">Faculty of Medicine Siriraj Hospital</institution>, <institution>Mahidol University</institution>, <addr-line><named-content content-type="city">Bangkok</named-content></addr-line>, <country>Thailand</country></aff><aff id="aff3"><label>3</label><institution content-type="dept">Bureau of Epidemiology, Department of Disease Control</institution>, <institution>Ministry of Public Health</institution>, <addr-line><named-content content-type="city">Nonthaburi</named-content></addr-line>, <country>Thailand</country></aff><aff id="aff4"><label>4</label><institution content-type="dept">Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine</institution>, <institution>University of Oxford</institution>, <addr-line><named-content content-type="city">Oxford</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff5"><label>5</label><institution>London School of Hygiene and Tropical Medicine</institution>, <addr-line><named-content content-type="city">London</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff6"><label>6</label><institution>University of Cambridge, Addenbrooke’s Hospital</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff7"><label>7</label><institution content-type="dept">Department of Tropical Hygiene, Faculty of Tropical Medicine</institution>, <institution>Mahidol University</institution>, <addr-line><named-content content-type="city">Bangkok</named-content></addr-line>, <country>Thailand</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Abdool Karim</surname><given-names>Quarraisha</given-names></name><role>Reviewing editor</role><aff id="aff8"><institution>University of KwaZulu Natal</institution>, <country>South Africa</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><email>direk@tropmedres.ac</email></corresp><fn fn-type="con" id="equal-contrib"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="pub" publication-format="electronic"><day>06</day><month>09</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>5</volume><elocation-id>e18082</elocation-id><history><date date-type="received"><day>23</day><month>05</month><year>2016</year></date><date date-type="accepted"><day>24</day><month>08</month><year>2016</year></date></history><permissions><copyright-statement>© 2016, Lim et al</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Lim et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-18082-v2.pdf"/><abstract><object-id pub-id-type="doi">10.7554/eLife.18082.001</object-id><p>Little is known about the excess mortality caused by multidrug-resistant (MDR) bacterial infection in low- and middle-income countries (LMICs). We retrospectively obtained microbiology laboratory and hospital databases of nine public hospitals in northeast Thailand from 2004 to 2010, and linked these with the national death registry to obtain the 30-day mortality outcome. The 30-day mortality in those with MDR community-acquired bacteraemia, healthcare-associated bacteraemia, and hospital-acquired bacteraemia were 35% (549/1555), 49% (247/500), and 53% (640/1198), respectively. We estimate that 19,122 of 45,209 (43%) deaths in patients with hospital-acquired infection due to MDR bacteria in Thailand in 2010 represented excess mortality caused by MDR. We demonstrate that national statistics on the epidemiology and burden of MDR in LMICs could be improved by integrating information from readily available databases. The prevalence and mortality attributable to MDR in Thailand are high. This is likely to reflect the situation in other LMICs.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.18082.001">http://dx.doi.org/10.7554/eLife.18082.001</ext-link></p></abstract><abstract abstract-type="executive-summary"><object-id pub-id-type="doi">10.7554/eLife.18082.002</object-id><title>eLife digest</title><p>Antimicrobial resistance is a global problem. Each year, an estimated 23,000 deaths in the United States and 25,000 deaths in the European Union are extra deaths caused by bacteria resistant to antibiotics. People in low- and middle-income countries are also using more antibiotics, in part because of rising incomes, lower costs of antibiotics, and a lack of control of antimicrobial usage in the hospitals and over-the-counter sales of the drugs. These factors are thought to be driving the development and spread of bacteria that are resistant to multiple antibiotics in countries such as China, India, Indonesia and Thailand. However, a lack of information makes it difficult to estimate the size of the problem and, then, to track how antimicrobial resistance and multi-drug resistance is changing over time in these and other low- and middle-income countries.</p><p>Now, by integrating routinely collected data from a range of databases, Lim, Takahashi et al. estimate that around an extra 19,000 deaths are caused by multi-drug resistant bacteria in Thailand each year. Thailand has a population of about 70 million, and so, per capita, this estimate is about 3 to 5 times larger than those for the United States and European Union (which have a populations of about 300 million and 500 million, respectively). Lim, Takahashi et al. also show that more of the bacteria collected from patients are resistant to multiple antimicrobial drugs and that the burden of antimicrobial resistance in Thailand is worsening over time.</p><p>These findings suggest that more studies with a systematic approach need to be done in other low- and middle-income countries, especially in countries where microbiological laboratories are readily available and routinely used. Further work is also needed to identify where resources and attentions are most needed to effectively fight against antimicrobial resistance in low- and middle-income countries.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.18082.002">http://dx.doi.org/10.7554/eLife.18082.002</ext-link></p></abstract><kwd-group kwd-group-type="author-keywords"><title>Author Keywords</title><kwd>antimicrobial resistant</kwd><kwd><italic>Staphylococcus aureus</italic></kwd><kwd><italic>K. pneumoniae</italic></kwd><kwd><italic>P. aeruginosa</italic></kwd><kwd>Enterococcus</kwd><kwd>Acinetobacter</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research Organism</title><kwd><italic>E. coli</italic></kwd><kwd>Other</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004397</institution-id><institution>Ministry of Public Health</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Limmathurotsakul</surname><given-names>Direk</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004440</institution-id><institution>Wellcome Trust</institution></institution-wrap></funding-source><award-id>100484/Z/12/Z</award-id><principal-award-recipient><name><surname>Lim</surname><given-names>Cherry</given-names></name><name><surname>Day</surname><given-names>Nicholas PJ</given-names></name><name><surname>Limmathurotsakul</surname><given-names>Direk</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004440</institution-id><institution>Wellcome Trust</institution></institution-wrap></funding-source><award-id>101103/Z/13/Z</award-id><principal-award-recipient><name><surname>Limmathurotsakul</surname><given-names>Direk</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>elife-xml-version</meta-name><meta-value>2.5</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>The burden of antimicrobial resistance in Thailand is deteriorating over time, and 19,122 deaths in the country in 2010 were excess deaths caused by multidrug-resistant bacterial infection.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The emergence of antimicrobial resistance (AMR) is of major medical concern, particularly in low- and middle-income countries (LMICs) (<xref ref-type="bibr" rid="bib29">World Health Organization, 2014</xref>; <xref ref-type="bibr" rid="bib14">Laxminarayan et al., 2013</xref>). In LMICs, antibiotic use is increasing with rising incomes, affordable antimicrobials and the lack of stewardship in hospital and poor control of over-the-counter sales. This is driving the emergence and spread of multidrug-resistant (MDR) pathogens in community and hospital settings. Hospital data from LMICs suggest that the cumulative incidence of community-acquired Extended-Spectrum Beta-Lactamase (ESBL) producing <italic>Escherichia coli</italic> and <italic>Klebsiella pneumoniae</italic> infections are increasing over time (<xref ref-type="bibr" rid="bib11">Kanoksil et al., 2013</xref>; <xref ref-type="bibr" rid="bib1">Ansari et al., 2015</xref>). A recent report from the International Nosocomial Infection Control Consortium (INICC) also showed that the prevalence of AMR organisms causing hospital-acquired infections (HAI) in ICUs in LMICs is much higher than those in the United States (US) (<xref ref-type="bibr" rid="bib28">Rosenthal et al., 2014</xref>).</p><p>Attributable mortality, generally defined as the difference in mortality between those with and without the condition of interest, is an important parameter used to estimate the burden of AMR. In the US, it is estimated that mortality from infection attributable to AMR is 6.5%, (<xref ref-type="bibr" rid="bib26">Roberts et al., 2009</xref>) leading to an estimate of 23,000 deaths attributable to AMR each year (<xref ref-type="bibr" rid="bib4">Center for Disease Controls and Prevention and U.S. Department of Health and Human Services, 2013</xref>). In the European Union, it is estimated that the number of deaths attributable to selected antibiotic-resistant bacteria is about 25,000 each year (<xref ref-type="bibr" rid="bib6">European Centre for Disease Prevention and Control and European Medicines Agency, 2009</xref>). There is limited information on mortality attributable to AMR in LMICs. The mortality attributable to ventilator-associated pneumonia in ICUs in Colombia, Peru, and Argentina is estimated to be 17%, 25%, and 35%, respectively, and is associated with a high percentage of AMR organisms (<xref ref-type="bibr" rid="bib18">Moreno et al., 2006</xref>; <xref ref-type="bibr" rid="bib5">Cuellar et al., 2008</xref>; <xref ref-type="bibr" rid="bib27">Rosenthal et al., 2003</xref>). The mortality attributable to ESBL and methicillin-resistance <italic>Staphylococcus aureus</italic> (MRSA) is estimated to be 27% and 34% in neonatal sepsis in Tanzania, respectively, (<xref ref-type="bibr" rid="bib12">Kayange et al., 2010</xref>) which has been used to postulate an estimate that 58,319 deaths could be attributable to ESBL and MRSA in India alone (<xref ref-type="bibr" rid="bib14">Laxminarayan et al., 2013</xref>). In an effort to harmonize the surveillance systems of AMR, a joint initiative between the European Centre for Disease Prevention and Control (ECDC) and the Centres for Disease Prevention and Control (CDC) have developed standard definitions of multidrug-resistance (MDR) (<xref ref-type="bibr" rid="bib15">Magiorakos et al., 2012</xref>).</p><p>We recently combined large data sets from multiple sources including microbiology databases, hospital admission databases, and the national death registry from a sample of ten public hospitals in northeast Thailand from 2004 to 2010 (<xref ref-type="bibr" rid="bib11">Kanoksil et al., 2013</xref>; <xref ref-type="bibr" rid="bib10">Hongsuwan et al., 2014</xref>). We defined community-acquired bacteraemia (CAB) as the isolation of a pathogenic bacterium from blood taken in the first 2 days of admission and without a hospital stay in the 30 days prior to admission, healthcare-associated bacteraemia (HCAB) as the isolation of a pathogenic bacterium from blood taken in the first 2 days of admission and with a hospital stay within 30 days prior to the admission, and hospital-acquired bacteraemia (HAB) as the isolation of a pathogenic bacterium from blood taken after the first 2 days of admission (<xref ref-type="bibr" rid="bib11">Kanoksil et al., 2013</xref>; <xref ref-type="bibr" rid="bib10">Hongsuwan et al., 2014</xref>). We reported an increase in the incidence of CAB, HCAB and HAB over the study period, and that bacteraemia was associated with high case fatality rates (37.5%, 41.8% and 45.5%, respectively) (<xref ref-type="bibr" rid="bib11">Kanoksil et al., 2013</xref>; <xref ref-type="bibr" rid="bib10">Hongsuwan et al., 2014</xref>). Here, we apply ECDC/CDC standard definitions of MDR to this large data set to evaluate the prevalence, trends, and mortality attributable to MDR bacteria isolated from the blood. We then estimate the number of deaths attributable to MDR in Thailand nationwide.</p></sec><sec id="s2" sec-type="results"><title>Results</title><p>We contacted all 20 provincial hospitals in Northeast Thailand to participate in the study. All provincial hospitals were equipped with all basic medical specialties and intensive care units (ICUs). Agreement was obtained from 15 (75%) hospitals, of which ten had hospital databases and microbiological laboratory databases as electronic files in a readily accessible format (<xref ref-type="bibr" rid="bib11">Kanoksil et al., 2013</xref>; <xref ref-type="bibr" rid="bib10">Hongsuwan et al., 2014</xref>). Of these ten hospitals, nine had databases of antimicrobial susceptibility testing results as electronic files for the study (<xref ref-type="fig" rid="fig1">Figure 1</xref>). The median bed number for the nine hospitals included in the analysis was 450 beds (range 300 to 1000 beds). Of these, three had data available for the period 2004–2010, two between 2007 and 2010, three between 2008 and 2010 and one between 2009 and 2010. Overall, 1,803,506 admission records from 1,255,571 patients were evaluated. A total of 20,803 (1.2%) admission records had at least one blood culture positive for pathogenic organisms during admission. Of 10,022 patients with first episodes of bacteraemia caused by <italic>S. aureus, Enterococcus</italic> spp, <italic>E. coli, K. pneumoniae, P. aeruginosa</italic> and <italic>Acinetobacter</italic> spp., 226 patients (2%) were excluded because the causative organisms were tested for susceptibility to fewer than three antimicrobial categories. Therefore, a total of 9796 first episodes of bacteraemia caused by <italic>S. aureus</italic> (n = 1881)<italic>, Enterococcus</italic> spp (n = 342), <italic>E. coli</italic> (n = 4279)<italic>, K. pneumoniae</italic> (n = 1661)<italic>, P aeruginosa</italic> (n = 568), and <italic>Acinetobacter</italic> spp. (n = 1065) were evaluated in the analysis. The proportion of bacteria being MDR was highest in HAB and lowest in CAB for all organisms (all p&lt;0.001 except for <italic>Enterococcus</italic> spp., <xref ref-type="table" rid="tbl1">Table 1</xref>).<fig id="fig1" position="float"><object-id pub-id-type="doi">10.7554/eLife.18082.003</object-id><label>Figure 1.</label><caption><title>Location of participating hospitals.</title><p>These were situated in (1) Nong Khai, (2) Udon Thani, (3) Nakhon Phanom, (4) Chaiyaphum, (5) Mukdahan, (6) Yasothon, (7) Burirum, (8) Sisaket, and (9) Ubon Ratchathani provinces.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.18082.003">http://dx.doi.org/10.7554/eLife.18082.003</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-18082-fig1-v2"/></fig><table-wrap id="tbl1" position="float"><object-id pub-id-type="doi">10.7554/eLife.18082.004</object-id><label>Table 1.</label><caption><p>Proportions of bacteraemias being caused by multidrug-resistant (MDR) variants of those bacteria.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.18082.004">http://dx.doi.org/10.7554/eLife.18082.004</ext-link></p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top">Pathogens</th><th valign="top">Community-acquired bacteraemia <break/>(CAB)</th><th valign="top">Healthcare-associated bacteraemia <break/>(HCAB)</th><th valign="top">Hospital-acquired bacteraemia <break/>(HAB)</th><th valign="top">p values</th></tr></thead><tbody><tr><td valign="top">MDR <italic>Staphylococcus aureus</italic></td><td valign="top">94/1176 (8%)</td><td valign="top">73/259 (28%)</td><td valign="top">222/446 (50%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">MDR <italic>Enterococcus</italic> spp</td><td valign="top">0/176 (0%)</td><td valign="top">0/49 (0%)</td><td valign="top">4/117 (3%)</td><td valign="top">0.02</td></tr><tr><td valign="top">MDR <italic>Escherichia coli</italic></td><td valign="top">1177/3382 (35%)</td><td valign="top">288/494 (58%)</td><td valign="top">252/403 (63%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">MDR <italic>Klebsiella pneumoniae</italic></td><td valign="top">146/1010 (14%)</td><td valign="top">71/196 (36%)</td><td valign="top">301/455 (66%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">MDR <italic>Pseudomonas aeruginosa</italic></td><td valign="top">13/286 (5%)</td><td valign="top">10/103 (10%)</td><td valign="top">45/179 (25%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">MDR <italic>Acinetobacter</italic> spp</td><td valign="top">125/449 (28%)</td><td valign="top">58/115 (50%)</td><td valign="top">374/501 (75%)</td><td valign="top">&lt;0.001</td></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><p>NOTE: CAB was defined as the isolation of a pathogenic bacterium from blood taken in the first 2 days of admission and without a hospital stay in the 30 days prior to admission. HCAB was defined as the isolation of a pathogenic bacterium from blood taken in the first 2 days of admission and with a hospital stay within 30 days prior to the admission. HAB was defined as the isolation of a pathogenic bacterium from blood taken after the first 2 days of admission.</p></fn></table-wrap-foot></table-wrap></p><sec id="s2-1"><title>Staphylococcus aureus</title><p>Of CAB, HCAB and HAB caused by <italic>S. aureus</italic>, 8%, 28%, and 50% were caused by MDR <italic>S. aureus</italic>, respectively (p&lt;0.001). Almost all MDR <italic>S. aureus</italic> were MRSA (92% [357/389], <xref ref-type="table" rid="tbl2">Table 2</xref>). We did not observe a trend in the proportion of <italic>S. aureus</italic> bacteraemia being caused by MRSA (<xref ref-type="fig" rid="fig2">Figure 2</xref>). Vancomycin non-susceptible <italic>S. aureus</italic> was found in &lt;1% of tested isolates (6/1380).<fig id="fig2" position="float"><object-id pub-id-type="doi">10.7554/eLife.18082.005</object-id><label>Figure 2.</label><caption><title>Trends in proportions of <italic>Staphylococcus aureus</italic> bacteraemia being caused by MRSA in Northeast Thailand.</title><p>(<bold>A</bold>) community-acquired, (<bold>B</bold>) healthcare-associated and (<bold>C</bold>) hospital-acquired <italic>Staphylococcus aureus</italic> bacteraemia.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.18082.005">http://dx.doi.org/10.7554/eLife.18082.005</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-18082-fig2-v2"/></fig><table-wrap id="tbl2" position="float"><object-id pub-id-type="doi">10.7554/eLife.18082.006</object-id><label>Table 2.</label><caption><p>Antibiogram of <italic>S. aureus</italic> causing bacteraemia in Northeast Thailand.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.18082.006">http://dx.doi.org/10.7554/eLife.18082.006</ext-link></p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top">Antibiotic category</th><th valign="top">Antibiotic agents</th><th valign="top">CAB <break/>(n = 1176 patients)</th><th valign="top">HCAB <break/>(n = 259 patients)</th><th valign="top">HAB <break/>(n = 446 patients)</th><th valign="top">p values</th></tr></thead><tbody><tr><td valign="top">Aminoglycosides</td><td valign="top">Gentamicin</td><td valign="top">24/484 (5%)</td><td valign="top">16/84 (19%)</td><td valign="top">66/151 (44%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Ansamycins</td><td valign="top">Rifampin</td><td valign="top">2/129 (2%)</td><td valign="top">1/19 (5%)</td><td valign="top">0/38 (0%)</td><td valign="top">0.37</td></tr><tr><td valign="top">Anti-MRSA cephalosporins</td><td valign="top">Ceftaroline</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">Cefamycins</td><td valign="top">Oxacillin *</td><td valign="top">80/1145 (7%)</td><td valign="top">67/247 (27%)</td><td valign="top">210/441 (48%)</td><td valign="top">&lt;0.001</td></tr><tr><td rowspan="2" valign="top">Fluoroquinolones</td><td valign="top">Ciprofloxacin</td><td valign="top">3/45 (7%)</td><td valign="top">2/8 (25%)</td><td valign="top">4/10 (40%)</td><td valign="top">0.01</td></tr><tr><td valign="top">Moxifloxacin</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">Folate pathway inhibitors</td><td valign="top">Trimethoprim-sulphamethoxazole</td><td valign="top">99/1139 (9%)</td><td valign="top">57/251 (23%)</td><td valign="top">185/438 (42%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Fucidanes</td><td valign="top">Fusidic acid</td><td valign="top">33/618 (5%)</td><td valign="top">4/170 (2%)</td><td valign="top">12/291 (4%)</td><td valign="top">0.26</td></tr><tr><td rowspan="3" valign="top">Glycopeptides</td><td valign="top">Vancomycin †</td><td valign="top">4/833 (0.5%)</td><td valign="top">0/190 (0%)</td><td valign="top">2/357 (1%)</td><td valign="top">0.86</td></tr><tr><td valign="top">Teicoplanin</td><td valign="top">2/66 (3%)</td><td valign="top">1/17 (6%)</td><td valign="top">0/17 (0%)</td><td valign="top">0.72</td></tr><tr><td valign="top">Telavancin</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">Glycylcyclines</td><td valign="top">Tigecycline</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">Lincosamides</td><td valign="top">Clindamycin</td><td valign="top">118/1147 (10%)</td><td valign="top">77/251 (31%)</td><td valign="top">202/438 (46%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Lipopeptides</td><td valign="top">Daptomycin</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">Macrolides</td><td valign="top">Erythromycin</td><td valign="top">138/1116 (12%)</td><td valign="top">76/240 (32%)</td><td valign="top">222/429 (52%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Oxazolidinones</td><td valign="top">Linezolid</td><td valign="top">0/81 (0%)</td><td valign="top">0/16 (0%)</td><td valign="top">0/32 (0%)</td><td valign="top">-</td></tr><tr><td valign="top">Phenicols</td><td valign="top">Chloramphenicol</td><td valign="top">6/86 (7%)</td><td valign="top">4/24 (17%)</td><td valign="top">2/14 (14%)</td><td valign="top">0.21</td></tr><tr><td valign="top">Phosphonic acids</td><td valign="top">Fosfomycin</td><td valign="top">14/361 (4%)</td><td valign="top">10/66 (15%)</td><td valign="top">24/141 (17%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Streptogramins</td><td valign="top">Quinupristin-dalfopristin</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td rowspan="3" valign="top">Tetracyclines</td><td valign="top">Tetracycline</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">Doxycycline</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">Minocycline</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">MDR</td><td valign="top"/><td valign="top">94/1176 (8%)</td><td valign="top">73/259 (28%)</td><td valign="top">222/446 (50%)</td><td valign="top">&lt;0.001</td></tr></tbody></table><table-wrap-foot><fn id="tblfn2"><p>NOTE: Data are number of isolates demonstrating non-susceptible to the antimicrobial over the total number of isolates tested (%). CAB = Community-acquired bacteraemia, HCAB = Healthcare-associated bacteraemia, HAB = Hospital-acquired bacteraemia, and NA = Not available. The first isolate of each patient was used. MDR (one or more of these have to apply): (i) an MRSA is always considered MDR by virtue of being an MRSA (ii) non-susceptible to ≥1 agent in ≥3 antimicrobial categories.</p></fn><fn id="tblfn3"><p>* Defined by using a 30 μg cefoxitin disc and an inhibition zone diameter of &lt;21 mm.</p></fn><fn id="tblfn4"><p>† Defined by using a 30 μg vancomycin disc and an inhibition zone diameter of &lt;15 mm.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="s2-2"><title><italic>Enterococcus</italic> species</title><p>MDR <italic>Enterococcus</italic> spp. were not found in CAB (0/176) and HCAB (0/49), while 3% (4/117) of <italic>Enterococcus</italic> spp. causing HAB were MDR. Of CAB caused by <italic>Enterococcus</italic> spp., 15% (20/134) and 23% (35/153) was non-susceptible to ampicillin and gentamicin, respectively (<xref ref-type="table" rid="tbl3">Table 3</xref>), while 42% (34/81) and 62% (63/101) of HAB caused by <italic>Enterococcus</italic> spp. were non-susceptible to those agents, respectively (both p&lt;0.001). Vancomycin non-susceptible <italic>Enterococcus</italic> spp. was found in 4% of tested isolates (15/338).</p></sec><sec id="s2-3"><title>Escherichia coli</title><p>Of CAB, HCAB and HAB caused by <italic>E. coli</italic>, 35%, 58% and 63% were caused by MDR <italic>E. coli</italic>, respectively (p&lt;0.001). Of <italic>E. coli</italic> causing CAB, 79% (2246/2843), 16% (501/3076), 24% (728/3000), 58% (1738/3007), and 17% (559/3346) were non-susceptible to commonly-used antimicrobials for community-acquired infections such as ampicillin, cefotaxime, ciprofloxacin, trimethoprim-sulphamethoxazole, and gentamicin, respectively (<xref ref-type="table" rid="tbl4">Table 4</xref>). From 2004 to 2010, the proportions of community-acquired <italic>E. coli</italic> bacteraemia being caused by <italic>E. coli</italic> non-susceptible to extended-spectrum cephalosporins rose from 5% (9/169) to 23% (186/815) (p=0.04) (<xref ref-type="fig" rid="fig3">Figure 3</xref>). The proportions of healthcare-associated and hospital-acquired <italic>E. coli</italic> bacteraemia being caused by <italic>E. coli</italic> non-susceptible to extended-spectrum cephalosporins were high (44% [204/465] and 52% [190/368], respectively), but a significant trend over time was not observed (p=0.18 and p=0.63, respectively). Carbapenem non-susceptible <italic>E. coli</italic> was found in &lt;1% of tested isolates (12/3838).<fig id="fig3" position="float"><object-id pub-id-type="doi">10.7554/eLife.18082.007</object-id><label>Figure 3.</label><caption><title>Trends in proportions of <italic>Escherichia coli</italic> bacteraemia being caused by <italic>E. coli</italic> non-susceptible to extended-spectrum cephalosporins in Northeast Thailand.</title><p>(<bold>A</bold>) community-acquired, (<bold>B</bold>) healthcare-associated and (<bold>C</bold>) hospital-acquired <italic>E. coli</italic> bacteraemia.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.18082.007">http://dx.doi.org/10.7554/eLife.18082.007</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-18082-fig3-v2"/></fig><table-wrap id="tbl3" position="float"><object-id pub-id-type="doi">10.7554/eLife.18082.008</object-id><label>Table 3.</label><caption><p>Antibiogram of <italic>Enterococcus</italic> spp. causing bacteraemia in Northeast Thailand.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.18082.008">http://dx.doi.org/10.7554/eLife.18082.008</ext-link></p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top">Antibiotic category</th><th valign="top">Antibiotic agents</th><th valign="top">CAB <break/>(n = 176 patients)</th><th valign="top">HCAB <break/>(n = 49 patients)</th><th valign="top">HAB <break/>(n = 117 patients)</th><th valign="top">p values</th></tr></thead><tbody><tr><td valign="top">Aminoglycosides</td><td valign="top">Gentamicin <break/>(high level)</td><td valign="top">35/153 (23%)</td><td valign="top">24/45 (53%)</td><td valign="top">63/101 (62%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Streptomycin</td><td valign="top">Streptomycin <break/>(high level)</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td rowspan="3" valign="top">Carbapenems*</td><td valign="top">Imipenem</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">Meropenem</td><td valign="top">1/1 (100%)</td><td valign="top">NA</td><td valign="top">3/5 (60%)</td><td valign="top">&gt;0.99</td></tr><tr><td valign="top">Doripenem</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td rowspan="3" valign="top">Fluoroquinolones</td><td valign="top">Ciprofloxacin</td><td valign="top">37/44 (84%)</td><td valign="top">9/10 (90%)</td><td valign="top">31/37 (84%)</td><td valign="top">&gt;0.99</td></tr><tr><td valign="top">Levofloxacin</td><td valign="top">5/18 (28%)</td><td valign="top">1/6 (17%)</td><td valign="top">11/15 (73%)</td><td valign="top">0.01</td></tr><tr><td valign="top">Moxifloxacin</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td rowspan="2" valign="top">Glycopeptides</td><td valign="top">Vancomycin</td><td valign="top">9/176 (5%)</td><td valign="top">0/49 (0%)</td><td valign="top">6/113 (5%)</td><td valign="top">0.27</td></tr><tr><td valign="top">Teicoplanin</td><td valign="top">0/11 (0%)</td><td valign="top">0/4 (0%)</td><td valign="top">0/10 (0%)</td><td valign="top">-</td></tr><tr><td valign="top">Glycylcyclines</td><td valign="top">Tigecycline</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">Lipopeptides</td><td valign="top">Daptomycin</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">Oxazolidinones</td><td valign="top">Linezolid</td><td valign="top">0/8 (0%)</td><td valign="top">0/2 (0%)</td><td valign="top">0/4 (0%)</td><td valign="top">-</td></tr><tr><td valign="top">Penicillins</td><td valign="top">Ampicillin</td><td valign="top">20/134 (15%)</td><td valign="top">6/37 (16%)</td><td valign="top">34/81 (42%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Streptogramins*</td><td valign="top">Quinupristin-dalfopristin</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td rowspan="2" valign="top">Tetracycline</td><td valign="top">Doxycycline</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">Minocycline</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">MDR</td><td valign="top"/><td valign="top">0/176 (0%)</td><td valign="top">0/49 (0%)</td><td valign="top">4/117 (3%)</td><td valign="top">0.02</td></tr></tbody></table><table-wrap-foot><fn id="tblfn5"><p>NOTE: Data are number of isolates demonstrating non-susceptible to the antimicrobial over the total number of isolates tested (%). CAB = Community-acquired bacteraemia, HCAB = Healthcare-associated bacteraemia, HAB = Hospital-acquired bacteraemia, and NA = Not available. The first isolate of each patient was used. MDR: non-susceptible to ≥1 agent in ≥3 antimicrobial categories.</p></fn><fn id="tblfn6"><p>*Intrinsic resistance in <italic>E. faecium</italic> against carbapenems and in <italic>E. faecalis</italic> against streptogramins. When a species has intrinsic resistance to an antimicrobial category, that category is removed prior to applying the criteria for the MDR definition and is not counted when calculating the number of categories to which the bacterial isolate is non-susceptible.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl4" position="float"><object-id pub-id-type="doi">10.7554/eLife.18082.009</object-id><label>Table 4.</label><caption><p>Antibiogram of <italic>E. coli</italic> causing bacteraemia in Northeast Thailand.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.18082.009">http://dx.doi.org/10.7554/eLife.18082.009</ext-link></p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top">Antibiotic category</th><th valign="top">Antibiotic agents</th><th valign="top">CAB <break/>(n = 3382 patients)</th><th valign="top">HCAB <break/>(n = 494 patients)</th><th valign="top">HAB <break/>(n = 403 patients)</th><th valign="top">p values</th></tr></thead><tbody><tr><td rowspan="4" valign="top">Aminoglycosides</td><td valign="top">Gentamicin</td><td valign="top">559/3346 (17%)</td><td valign="top">166/484 (34%)</td><td valign="top">178/398 (45%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Tobramycin</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">Amikacin</td><td valign="top">72/2685 (3%)</td><td valign="top">26/397 (7%)</td><td valign="top">32/326 (10%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Netilmicin</td><td valign="top">68/1394 (5%)</td><td valign="top">25/259 (10%)</td><td valign="top">42/254 (17%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Anti-MRSA cephalosporins</td><td valign="top">Ceftaroline</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td rowspan="2" valign="top">Antipseudomonal penicillins + β lactamase inhibitors</td><td valign="top">Ticarcillin-clauvanic acid</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">Piperacillin-tazobactam</td><td valign="top">23/511 (5%)</td><td valign="top">10/103 (10%)</td><td valign="top">15/89 (17%)</td><td valign="top">&lt;0.001</td></tr><tr><td rowspan="3" valign="top">Carbapenems</td><td valign="top">Ertapenem</td><td valign="top">4/1325 (&lt;1%)</td><td valign="top">1/235 (&lt;1%)</td><td valign="top">4/205 (2%)</td><td valign="top">0.02</td></tr><tr><td valign="top">Imipenem</td><td valign="top">3/2449 (&lt;1%)</td><td valign="top">0/386 (0%)</td><td valign="top">3/344 (1%)</td><td valign="top">0.04</td></tr><tr><td valign="top">Meropenem</td><td valign="top">0/1988 (0%)</td><td valign="top">1/314 (&lt;1%)</td><td valign="top">1/244 (&lt;1%)</td><td valign="top">0.05</td></tr><tr><td rowspan="2" valign="top">Non-extended spectrum cephalosporins</td><td valign="top">Cefazolin</td><td valign="top">468/1095 (43%)</td><td valign="top">115/174 (66%)</td><td valign="top">80/102 (78%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Cefuroxime</td><td valign="top">219/1438 (15%)</td><td valign="top">96/226 (42%)</td><td valign="top">102/202 (50%)</td><td valign="top">&lt;0.001</td></tr><tr><td rowspan="3" valign="top">Extended-spectrum cephalosporins</td><td valign="top">Cefotaxime</td><td valign="top">501/3076 (16%)</td><td valign="top">199/455 (44%)</td><td valign="top">185/361 (51%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Ceftazidime</td><td valign="top">392/3020 (13%)</td><td valign="top">165/446 (37%)</td><td valign="top">164/351 (47%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Cefepime</td><td valign="top">30/293 (10%)</td><td valign="top">12/42 (29%)</td><td valign="top">18/53 (34%)</td><td valign="top">&lt;0.001</td></tr><tr><td rowspan="2" valign="top">Cephamycins</td><td valign="top">Cefoxitin</td><td valign="top">36/1200 (3%)</td><td valign="top">16/215 (7%)</td><td valign="top">16/195 (8%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Cefotetan</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">Fluoroquinolones</td><td valign="top">Ciprofloxacin</td><td valign="top">728/3000 (24%)</td><td valign="top">221/452 (49%)</td><td valign="top">171/384 (45%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Folate pathway inhibitors</td><td valign="top">Trimethoprim-sulphamethoxazole</td><td valign="top">1738/3007 (58%)</td><td valign="top">294/442 (67%)</td><td valign="top">225/350 (64%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Glycylcyclines</td><td valign="top">Tigecycline</td><td valign="top">0/7 (0%)</td><td valign="top">NA</td><td valign="top">0/1 (0%)</td><td valign="top">-</td></tr><tr><td valign="top">Monobactams</td><td valign="top">Aztreonam</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">Penicillins</td><td valign="top">Ampicillin</td><td valign="top">2246/2843 (79%)</td><td valign="top">371/420 (88%)</td><td valign="top">301/342 (88%)</td><td valign="top">&lt;0.001</td></tr><tr><td rowspan="2" valign="top">Penicillins + β lactamase inhibitors</td><td valign="top">Amoxicillin-clavulanic acid</td><td valign="top">790/3074 (26%)</td><td valign="top">191/463 (41%)</td><td valign="top">158/373 (42%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Ampicillin-sulbactam</td><td valign="top">83/296 (28%)</td><td valign="top">18/48 (38%)</td><td valign="top">12/25 (48%)</td><td valign="top">0.06</td></tr><tr><td valign="top">Phenicols</td><td valign="top">Chloramphenicol</td><td valign="top">14/63 (22%)</td><td valign="top">1/4 (25%)</td><td valign="top">3/5 (60%)</td><td valign="top">0.14</td></tr><tr><td valign="top">Phosphonic acids</td><td valign="top">Fosfomycin</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">Polymyxins</td><td valign="top">Colistin*</td><td valign="top">2/34 (6%)</td><td valign="top">0/6 (0%)</td><td valign="top">1/6 (17%)</td><td valign="top">0.61</td></tr><tr><td valign="top">MDR</td><td valign="top"/><td valign="top">1177/3382 (35%)</td><td valign="top">288/494 (58%)</td><td valign="top">252/403 (63%)</td><td valign="top">&lt;0.001</td></tr></tbody></table><table-wrap-foot><fn id="tblfn7"><p>NOTE: Data are number of isolates demonstrating non-susceptible to the antimicrobial over the total number of isolates tested (%). CAB = Community-acquired bacteraemia, HCAB = Healthcare-associated bacteraemia, HAB = Hospital-acquired bacteraemia, and NA = Not available. The first isolate of each patient was used. MDR: non-susceptible to ≥1 agent in ≥3 antimicrobial categories.</p></fn><fn id="tblfn8"><p>*Defined by using an inhibition zone of &lt;11 mm.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="s2-4"><title>Klebsiella pneumoniae</title><p>Of CAB, HCAB and HAB caused by <italic>K. pneumoniae,</italic> 14%, 36%, and 66% were caused by MDR <italic>K. pneumoniae</italic>, respectively (p&lt;0.001). Of <italic>K. pneumoniae</italic> causing CAB, 16% (146/902), 16% (143/894), 23% (198/876), and 9% (94/999) were non-susceptible to cefotaxime, ciprofloxacin, trimethoprim-sulphamethoxazole and gentamicin, respectively (<xref ref-type="table" rid="tbl5">Table 5</xref>). From 2004 to 2010, the proportions of community-acquired <italic>K. pneumoniae</italic> bacteraemia being caused by <italic>K. pneumoniae</italic> non-susceptible to extended-spectrum cephalosporins rose from 12% (6/50) to 24% (64/263) (p=0.04) (<xref ref-type="fig" rid="fig4">Figure 4</xref>). The proportions of healthcare-associated and hospital-acquired <italic>K. pneumoniae</italic> bacteraemia being caused by <italic>K. pneumoniae</italic> non-susceptible to extended-spectrum cephalosporins were also high (40% [71/177] and 71% [304/431], respectively), but a significant trend over time was not observed (p=0.16 and p=0.35, respectively). Carbapenem non-susceptible <italic>K. pneumoniae</italic> was found in &lt;1% of tested isolates (11/1555).<fig id="fig4" position="float"><object-id pub-id-type="doi">10.7554/eLife.18082.010</object-id><label>Figure 4.</label><caption><title>Trends in proportions of <italic>Klebsiella pneumoniae</italic> bacteraemia being caused by <italic>K. pneumoniae</italic> non-susceptible to extended-spectrum cephalosporins in Northeast Thailand.</title><p>(<bold>A</bold>) community-acquired, (<bold>B</bold>) healthcare-associated and (<bold>C</bold>) hospital-acquired <italic>K. pneumoniae</italic> bacteraemia.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.18082.010">http://dx.doi.org/10.7554/eLife.18082.010</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-18082-fig4-v2"/></fig><table-wrap id="tbl5" position="float"><object-id pub-id-type="doi">10.7554/eLife.18082.011</object-id><label>Table 5.</label><caption><p>Antibiogram of <italic>K. pneumoniae</italic> causing bacteraemia in Northeast Thailand.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.18082.011">http://dx.doi.org/10.7554/eLife.18082.011</ext-link></p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top">Antibiotic category</th><th valign="top">Antibiotic agents</th><th valign="top">CAB <break/>(n = 1010 patients)</th><th valign="top">HCAB <break/>(n = 196 patients)</th><th valign="top">HAB <break/>(n = 455 patients)</th><th valign="top">p values</th></tr></thead><tbody><tr><td rowspan="4" valign="top">Aminoglycosides</td><td valign="top">Gentamicin</td><td valign="top">94/999 (9%)</td><td valign="top">53/193 (27%)</td><td valign="top">265/444 (60%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Tobramycin</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">Amikacin</td><td valign="top">17/815 (2%)</td><td valign="top">12/157 (8%)</td><td valign="top">109/398 (27%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Netilmicin</td><td valign="top">20/450 (4%)</td><td valign="top">23/112 (21%)</td><td valign="top">124/320 (39%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Anti-MRSA cephalosporins</td><td valign="top">Ceftaroline</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td rowspan="2" valign="top">Antipseudomonal penicillins + β lactamase inhibitors</td><td valign="top">Ticarcillin-clauvanic acid</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">Piperacillin-tazobactam</td><td valign="top">24/166 (14%)</td><td valign="top">14/32 (44%)</td><td valign="top">73/121 (60%)</td><td valign="top">&lt;0.001</td></tr><tr><td rowspan="3" valign="top">Carbapenems</td><td valign="top">Ertapenem</td><td valign="top">2/432 (0%)</td><td valign="top">1/100 (1%)</td><td valign="top">5/264 (2%)</td><td valign="top">0.17</td></tr><tr><td valign="top">Imipenem</td><td valign="top">1/778 (0%)</td><td valign="top">1/164 (1%)</td><td valign="top">2/408 (0%)</td><td valign="top">0.24</td></tr><tr><td valign="top">Meropenem</td><td valign="top">0/583 (0%)</td><td valign="top">1/113 (1%)</td><td valign="top">2/317 (1%)</td><td valign="top">0.10</td></tr><tr><td rowspan="2" valign="top">Non-extended spectrum cephalosporins</td><td valign="top">Cefazolin</td><td valign="top">76/319 (24%)</td><td valign="top">30/60 (50%)</td><td valign="top">101/127 (80%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Cefuroxime</td><td valign="top">81/478 (17%)</td><td valign="top">35/98 (36%)</td><td valign="top">161/231 (70%)</td><td valign="top">&lt;0.001</td></tr><tr><td rowspan="3" valign="top">Extended-spectrum cephalosporins</td><td valign="top">Cefotaxime</td><td valign="top">146/902 (16%)</td><td valign="top">71/173 (41%)</td><td valign="top">298/424 (70%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Ceftazidime</td><td valign="top">124/927 (13%)</td><td valign="top">63/176 (36%)</td><td valign="top">295/430 (69%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Cefepime</td><td valign="top">5/100 (5%)</td><td valign="top">8/22 (36%)</td><td valign="top">25/51 (49%)</td><td valign="top">&lt;0.001</td></tr><tr><td rowspan="2" valign="top">Cephamycins</td><td valign="top">Cefoxitin</td><td valign="top">15/396 (4%)</td><td valign="top">10/95 (11%)</td><td valign="top">14/230 (6%)</td><td valign="top">0.03</td></tr><tr><td valign="top">Cefotetan</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">Fluoroquinolones</td><td valign="top">Ciprofloxacin</td><td valign="top">143/894 (16%)</td><td valign="top">66/176 (38%)</td><td valign="top">187/430 (43%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Folate pathway inhibitors</td><td valign="top">Trimethoprim-sulphamethoxazole</td><td valign="top">198/876 (23%)</td><td valign="top">69/171 (40%)</td><td valign="top">219/407 (54%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Glycylcyclines</td><td valign="top">Tigecycline</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">Monobactams</td><td valign="top">Aztreonam</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td rowspan="2" valign="top">Penicillins + β lactamase inhibitors</td><td valign="top">Amoxicillin-clavulanic acid</td><td valign="top">131/945 (14%)</td><td valign="top">68/183 (37%)</td><td valign="top">291/443 (66%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Ampicillin-sulbactam</td><td valign="top">20/105 (19%)</td><td valign="top">9/17 (53%)</td><td valign="top">23/38 (61%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Phenicols</td><td valign="top">Chloramphenicol</td><td valign="top">4/19 (21%)</td><td valign="top">0/2 (0%)</td><td valign="top">0/3 (0%)</td><td valign="top">&gt;0.99</td></tr><tr><td valign="top">Phosphonic acids</td><td valign="top">Fosfomycin</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">Polymyxins</td><td valign="top">Colistin *</td><td valign="top">0/6 (0%)</td><td valign="top">0/2 (0%)</td><td valign="top">0/5 (0%)</td><td valign="top">-</td></tr><tr><td valign="top">MDR</td><td valign="top"/><td valign="top">146/1010 (14%)</td><td valign="top">71/196 (36%)</td><td valign="top">301/455 (66%)</td><td valign="top">&lt;0.001</td></tr></tbody></table><table-wrap-foot><fn id="tblfn9"><p>NOTE: Data are number of isolates demonstrating non-susceptible to the antimicrobial over the total number of isolates tested (%). CAB = Community-acquired bacteraemia, HCAB = Healthcare-associated bacteraemia, HAB = Hospital-acquired bacteraemia, and NA = Not available. The first isolate of each patient was used. MDR: non-susceptible to ≥1 agent in ≥3 antimicrobial categories.</p></fn><fn id="tblfn10"><p>* Defined by using an inhibition zone of &lt;11 mm.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="s2-5"><title>Pseudomonas aeruginosa</title><p>Of CAB, HCAB and HAB caused by <italic>P. aeruginosa,</italic> 5%, 10%, and 25% were caused by MDR <italic>P. aeruginosa</italic>, respectively (p&lt;0.001). Of <italic>P. aeruginosa</italic> causing HAB, 38% (68/179), 27% (48/177), 23% (39/169) and 26% (42/164) were non-susceptible to commonly-used antimicrobials for HAI such as ceftazidime, amikacin, ciprofloxacin and carbapenems, respectively (<xref ref-type="table" rid="tbl6">Table 6</xref>). We did not observe a trend in the proportions of <italic>P. aeruginosa</italic> being caused by <italic>P. aeruginosa</italic> that were non-susceptible to any specific antibiotic group (<xref ref-type="fig" rid="fig5">Figure 5</xref>).<fig id="fig5" position="float"><object-id pub-id-type="doi">10.7554/eLife.18082.012</object-id><label>Figure 5.</label><caption><title>Trends in proportions of <italic>Pseudomonas aeruginosa</italic> bacteraemia being caused by <italic>P. aeruginosa</italic> non-susceptible to carbapenem in Northeast Thailand.</title><p>(<bold>A</bold>) community-acquired, (<bold>B</bold>) healthcare-associated and (<bold>C</bold>) hospital-acquired <italic>Pseudomonas aeruginosa</italic> bacteraemia.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.18082.012">http://dx.doi.org/10.7554/eLife.18082.012</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-18082-fig5-v2"/></fig><table-wrap id="tbl6" position="float"><object-id pub-id-type="doi">10.7554/eLife.18082.013</object-id><label>Table 6.</label><caption><p>Antibiogram of <italic>P. aeruginosa</italic> causing bacteraemia in Northeast Thailand.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.18082.013">http://dx.doi.org/10.7554/eLife.18082.013</ext-link></p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top">Antibiotic category</th><th valign="top">Antibiotic agents</th><th valign="top">CAB <break/>(n = 286 patients)</th><th valign="top">HCAB <break/>(n = 103 patients)</th><th valign="top">HAB <break/>(n = 179 patients)</th><th valign="top">p values</th></tr></thead><tbody><tr><td rowspan="4" valign="top">Aminoglycosides</td><td valign="top">Gentamicin</td><td valign="top">29/235 (12%)</td><td valign="top">13/88 (15%)</td><td valign="top">60/140 (43%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Tobramycin</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">Amikacin</td><td valign="top">27/284 (10%)</td><td valign="top">13/100 (13%)</td><td valign="top">48/177 (27%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Netilmicin</td><td valign="top">8/155 (5%)</td><td valign="top">5/67 (7%)</td><td valign="top">34/120 (28%)</td><td valign="top">&lt;0.001</td></tr><tr><td rowspan="3" valign="top">Antipseudomonal carbapenems</td><td valign="top">Imipenem</td><td valign="top">14/238 (6%)</td><td valign="top">6/86 (7%)</td><td valign="top">37/154 (24%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Meropenem</td><td valign="top">9/163 (6%)</td><td valign="top">8/73 (11%)</td><td valign="top">24/125 (19%)</td><td valign="top">0.001</td></tr><tr><td valign="top">Doripenem</td><td valign="top">2/17 (12%)</td><td valign="top">0/3 (0%)</td><td valign="top">2/2 (100%)</td><td valign="top">0.04</td></tr><tr><td rowspan="2" valign="top">Antipseudomonal cephalosporins</td><td valign="top">Ceftazidime</td><td valign="top">29/280 (10%)</td><td valign="top">16/103 (16%)</td><td valign="top">68/179 (38%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Cefepime</td><td valign="top">2/36 (6%)</td><td valign="top">2/18 (11%)</td><td valign="top">10/28 (36%)</td><td valign="top">0.01</td></tr><tr><td rowspan="2" valign="top">Antipseudomonal fluoroquinolones</td><td valign="top">Ciprofloxacin</td><td valign="top">24/275 (9%)</td><td valign="top">12/101 (12%)</td><td valign="top">39/169 (23%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Levofloxacin</td><td valign="top">0/1 (0%)</td><td valign="top">1/1 (100%)</td><td valign="top">1/1 (100%)</td><td valign="top">&gt;0.99</td></tr><tr><td rowspan="2" valign="top">Antipseudomonal penicillins + β lactamase inhibitors</td><td valign="top">Ticarcillin-clauvanic acid</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">Piperacillin-tazobactam</td><td valign="top">8/85 (9%)</td><td valign="top">6/38 (16%)</td><td valign="top">8/46 (17%)</td><td valign="top">0.37</td></tr><tr><td valign="top">Monobactams</td><td valign="top">Aztreonam</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">Phosphonic acids</td><td valign="top">Fosfomycin</td><td valign="top">1/1 (100%)</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">Polymyxins</td><td valign="top">Colistin</td><td valign="top">0/7 (0%)</td><td valign="top">0/3 (0%)</td><td valign="top">1/7 (14%)</td><td valign="top">&gt;0.99</td></tr><tr><td valign="top"/><td valign="top">Polymyxin B</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">MDR</td><td valign="top"/><td valign="top">13/286 (5%)</td><td valign="top">10/103 (10%)</td><td valign="top">45/179 (25%)</td><td valign="top">&lt;0.001</td></tr></tbody></table><table-wrap-foot><fn id="tblfn11"><p>NOTE: Data are number of isolates demonstrating non-susceptible to the antimicrobial over the total number of isolates tested (%). CAB = Community-acquired bacteraemia, HCAB = Healthcare-associated bacteraemia, HAB = Hospital-acquired bacteraemia, and NA = Not available. The first isolate of each patient was used. MDR: non-susceptible to ≥1 agent in ≥3 antimicrobial categories.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="s2-6"><title><italic>Acinetobacter</italic> species</title><p>Of CAB, HCAB and HAB caused by <italic>Acinetobacter</italic> spp., 28%, 50%, and 75% were caused by MDR <italic>Acinetobacter</italic> spp., respectively (p&lt;0.001). Of <italic>Acinetobacter</italic> spp. causing HAB, 75% (377/500), 63% (310/495), 67% (322/481) and 64% (315/490) were non-susceptible to ceftazidime, amikacin, ciprofloxacin and carbapenems, respectively (<xref ref-type="table" rid="tbl7">Table 7</xref>). There was borderline evidence that the proportion of hospital-acquired <italic>Acinetobacter spp.</italic> bacteraemia being caused by <italic>Acinetobacter spp.</italic> non-susceptible to carbapenem rose from 49% (19/39) in 2004 to 65% (70/108) in 2010 (p=0.10) (<xref ref-type="fig" rid="fig6">Figure 6</xref>). Non-susceptibility to colistin was observed in 3% of tested isolates (2/63).<fig id="fig6" position="float"><object-id pub-id-type="doi">10.7554/eLife.18082.014</object-id><label>Figure 6.</label><caption><title>Trends in proportions of <italic>Acinetobacter</italic> spp bacteraemia being caused by <italic>Acinetobacter</italic> spp non-susceptible to carbapenem in Northeast Thailand.</title><p>(<bold>A</bold>) community-acquired, (<bold>B</bold>) healthcare-associated and (<bold>C</bold>) hospital-acquired <italic>Acinetobacter</italic> spp bacteraemia.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.18082.014">http://dx.doi.org/10.7554/eLife.18082.014</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-18082-fig6-v2"/></fig><table-wrap id="tbl7" position="float"><object-id pub-id-type="doi">10.7554/eLife.18082.015</object-id><label>Table 7.</label><caption><p>Antibiogram of <italic>Acinetobacter</italic> spp. causing bacteraemia in Northeast Thailand.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.18082.015">http://dx.doi.org/10.7554/eLife.18082.015</ext-link></p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top">Antibiotic category</th><th valign="top">Antibiotic agents</th><th valign="top">CAB <break/>(n = 449 patients)</th><th valign="top">HCAB <break/>(n = 115 patients)</th><th valign="top">HAB <break/>(n = 501 patients)</th><th valign="top">p values</th></tr></thead><tbody><tr><td rowspan="4" valign="top">Aminoglycosides</td><td valign="top">Gentamicin</td><td valign="top">112/390 (29%)</td><td valign="top">45/105 (43%)</td><td valign="top">310/455 (68%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Tobramycin</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">Amikacin</td><td valign="top">123/442 (28%)</td><td valign="top">45/112 (40%)</td><td valign="top">310/495 (63%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Netilmicin</td><td valign="top">44/203 (22%)</td><td valign="top">24/64 (38%)</td><td valign="top">224/381 (59%)</td><td valign="top">&lt;0.001</td></tr><tr><td rowspan="3" valign="top">Antipseudomonal carbapenems</td><td valign="top">Imipenem</td><td valign="top">87/397 (22%)</td><td valign="top">37/102 (36%)</td><td valign="top">293/459 (64%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Meropenem</td><td valign="top">65/284 (23%)</td><td valign="top">32/81 (40%)</td><td valign="top">229/348 (66%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Doripenem</td><td valign="top">16/45 (36%)</td><td valign="top">9/10 (90%)</td><td valign="top">6/7 (86%)</td><td valign="top">0.001</td></tr><tr><td rowspan="2" valign="top">Antipseudomonal fluoroquinolones</td><td valign="top">Ciprofloxacin</td><td valign="top">84/413 (20%)</td><td valign="top">53/106 (50%)</td><td valign="top">322/481 (67%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Levofloxacin</td><td valign="top">2/5 (40%)</td><td valign="top">2/2 (100%)</td><td valign="top">8/9 (89%)</td><td valign="top">0.11</td></tr><tr><td rowspan="2" valign="top">Antipseudomonal penicillins + β lactamase inhibitors</td><td valign="top">Ticarcillin- clauvanic acid</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">Piperacillin-tazobactam</td><td valign="top">22/98 (22%)</td><td valign="top">13/28 (46%)</td><td valign="top">74/106 (70%)</td><td valign="top">&lt;0.001</td></tr><tr><td rowspan="3" valign="top">Extended-spectrum cephalosporins</td><td valign="top">Cefotaxime</td><td valign="top">242/291 (83%)</td><td valign="top">89/94 (95%)</td><td valign="top">407/420 (97%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Ceftazidime</td><td valign="top">133/448 (30%)</td><td valign="top">61/114 (54%)</td><td valign="top">377/500 (75%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Cefepime</td><td valign="top">18/53 (34%)</td><td valign="top">10/22 (45%)</td><td valign="top">95/133 (71%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Folate pathway inhibitor</td><td valign="top">Trimethopri-sulphamethoxazole</td><td valign="top">119/356 (33%)</td><td valign="top">55/99 (56%)</td><td valign="top">333/435 (77%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Penicillins + β lactamase inhibitors</td><td valign="top">Ampicillin-sulbactam</td><td valign="top">43/134 (32%)</td><td valign="top">16/29 (55%)</td><td valign="top">79/115 (69%)</td><td valign="top">&lt;0.001</td></tr><tr><td rowspan="2" valign="top">Polymyxins</td><td valign="top">Colistin *</td><td valign="top">2/16 (13%)</td><td valign="top">0/14 (0%)</td><td valign="top">0/33 (0%)</td><td valign="top">0.11</td></tr><tr><td valign="top">Polymyxin B</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td rowspan="3" valign="top">Tetracyclines</td><td valign="top">Tetracycline</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">Doxycycline</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">Minocycline</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">MDR</td><td valign="top"/><td valign="top">125/449 (28%)</td><td valign="top">58/115 (50%)</td><td valign="top">374/501 (75%)</td><td valign="top">&lt;0.001</td></tr></tbody></table><table-wrap-foot><fn id="tblfn12"><p>NOTE: Data are number of isolates demonstrating non-susceptible to the antimicrobial over the total number of isolates tested (%). CAB = Community-acquired bacteraemia, HCAB = Healthcare-associated bacteraemia, HAB = Hospital-acquired bacteraemia, and NA = Not available. The first isolate of each patient was used. MDR: non-susceptible to ≥1 agent in ≥3 antimicrobial categories.</p></fn><fn id="tblfn13"><p>* Defined by using an inhibition zone of &lt;11 mm.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="s2-7"><title>Mortality attributable to MDR</title><p>The 30-day mortality in patients with CAB, HCAB and HAB caused by MDR bacteria was 35% (549/1555), 49% (247/500), and 53% (640/1198), compared with 32% (1595/4924), 37% (264/716), and 42% (383/903) in CAB, HCAB, and HAB caused by non-MDR bacteria, respectively (<xref ref-type="fig" rid="fig7">Figure 7</xref>). In the final multivariable logistic regression model, gender, age group, year of admission and time to bacteraemia (for HAB) were included (<xref ref-type="supplementary-material" rid="SD3-data">Supplementary file 2</xref>).<fig id="fig7" position="float"><object-id pub-id-type="doi">10.7554/eLife.18082.016</object-id><label>Figure 7.</label><caption><title>Forest plot of mortality in patients with MDR bacteraemia compared with non-MDR bacteraemia in Northeast Thailand.</title><p>(<bold>A</bold>) Community-acquired bacteraemia. (<bold>B</bold>) Healthcare-associated bacteraemia. (<bold>C</bold>) Hospital-acquired bacteraemia.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.18082.016">http://dx.doi.org/10.7554/eLife.18082.016</ext-link></p><p><supplementary-material id="SD1-data"><object-id pub-id-type="doi">10.7554/eLife.18082.017</object-id><label>Figure 7—source data 1.</label><caption><title>Mortality in patients with MDR and non-MDR bacteraemia in Northeast Thailand.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.18082.017">http://dx.doi.org/10.7554/eLife.18082.017</ext-link></p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-18082-fig7-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-18082-fig7-v2"/></fig></p><p>If excess mortality in patients infected with MDR bacteria after adjusting for confounding factors in the final multivariable model is assumed to be caused by MDR, the mortality attributable to MDR was 7% (95%CI 4% to 10%, p&lt;0.001) in CAB, 15% (95%CI 5% to 24%, p&lt;0.001) in HCAB and 15% (95%CI 2% to 27%, p&lt;0.001) in HAB (<xref ref-type="fig" rid="fig7">Figure 7</xref>). Heterogeneity between different organisms was clearly observed in HAB (p&lt;0.001), and borderline evidence of heterogeneity was observed in HCAB (p=0.09). The heterogeneity observed in HCAB and HAB was largely caused by MDR <italic>Acinetobacter</italic> spp. (<xref ref-type="fig" rid="fig7">Figure 7B and C</xref>). Mortality attributed to MDR was highest for hospital-acquired MDR <italic>Acinetobacter</italic> bacteraemia (41%).</p><p>Using our estimated mortality attributed to MDR bacteraemia (<xref ref-type="fig" rid="fig7">Figure 7C</xref>) and national statistics of HAI caused by MDR bacteria, we further estimated that 19,122 of 45,209 (43%) deaths in patients with HAI due to MDR bacteria in Thailand in 2010 represented excess mortality caused by MDR (<xref ref-type="table" rid="tbl8">Table 8</xref>). All parameters used to estimate the number of excess deaths in Thailand are shown in <xref ref-type="supplementary-material" rid="SD3-data">Supplementary file 2</xref>.<table-wrap id="tbl8" position="float"><object-id pub-id-type="doi">10.7554/eLife.18082.018</object-id><label>Table 8.</label><caption><p>Estimates of mortality attributable to multidrug-resistance (MDR) in hospital-acquired infection (HAI) in Thailand.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.18082.018">http://dx.doi.org/10.7554/eLife.18082.018</ext-link></p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top">Pathogens</th><th valign="top">No of patients*</th><th valign="top">Estimated mortality (%)<sup>†</sup></th><th valign="top">Estimated mortality if the infections were caused by non-MDR organisms (%)<sup>†, ‡</sup></th><th valign="top">Estimated excess mortality caused by MDR (%)<sup>†, ‡</sup></th></tr></thead><tbody><tr><td valign="top">MDR <italic>Staphylococcus aureus</italic></td><td valign="top">18,725</td><td valign="top">8262 (44%)</td><td valign="top">5463 (29%)</td><td valign="top">2799 (15%)</td></tr><tr><td valign="top">MDR <italic>Escherichia coli</italic></td><td valign="top">11,116</td><td valign="top">2163 (19%)</td><td valign="top">1566 (14%)</td><td valign="top">597 (5%)</td></tr><tr><td valign="top">MDR <italic>Klebsiella pneumoniae</italic></td><td valign="top">15,239</td><td valign="top">5267 (35%)</td><td valign="top">4979 (33%)</td><td valign="top">288 (2%)</td></tr><tr><td valign="top">MDR <italic>Pseudomonas aeruginosa</italic></td><td valign="top">6118</td><td valign="top">3966 (65%)</td><td valign="top">3696 (60%)</td><td valign="top">270 (4%)</td></tr><tr><td valign="top">MDR <italic>Acinetobacter</italic> spp</td><td valign="top">36,553</td><td valign="top">25,551 (70%)</td><td valign="top">10,383 (28%)</td><td valign="top">15,168 (41%)</td></tr><tr><td valign="top">Total</td><td valign="top">87,751</td><td valign="top">45,209 (52%)</td><td valign="top">26,087 (30%)</td><td valign="top">19,122 (22%)</td></tr></tbody></table><table-wrap-foot><fn id="tblfn14"><p><bold>*</bold>Cumulative incidence of antimicrobial resistant HAI in Thailand 2010 estimated by <xref ref-type="bibr" rid="bib25">Pumart et al. (2012)</xref>.</p></fn><fn id="tblfn15"><p><bold><sup>†</sup></bold>All parameters used to estimate the mortality and excess mortality are shown in <xref ref-type="supplementary-material" rid="SD3-data">Supplementary file 2</xref>.</p></fn><fn id="tblfn16"><p><sup>‡</sup>Excess mortality caused by MDR (mortality attributable to MDR) was defined as the difference in mortality of patients with MDR infection and their mortality if they were infected with non-MDR infections.</p></fn></table-wrap-foot></table-wrap></p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>This study presents detailed antimicrobial susceptibility data on common pathogenic bacteria, the association of MDR with infection acquisition (community-acquired, healthcare-associated and hospital-acquired), and excess mortality from MDR in a developing country. Our estimate of excess deaths caused by MDR in HAI patients in Thailand (19,122 deaths per year in a country of about 66 million population in 2010) is large compared to those estimated in USA (23,000 death per year in a country of 316 million population in 2013) (<xref ref-type="bibr" rid="bib4">Center for Disease Controls and Prevention and U.S. Department of Health and Human Services, 2013</xref>) and the European Union (25,000 deaths per year in EU of about 500 million population in 2007) (<xref ref-type="bibr" rid="bib6">European Centre for Disease Prevention and Control and European Medicines Agency, 2009</xref>). Our study highlights the need for public health officials and international health organizations to improve systems to track and reduce the burden of AMR in LMICs. Our estimated mortality for those with MDR HAI (45,209, <xref ref-type="table" rid="tbl2">Table 2</xref>) is higher than those previously published by Pumart et al. (38,481) (<xref ref-type="bibr" rid="bib25">Pumart et al., 2012</xref>), probably because we used 30-day mortality rather than in-hospital mortality.</p><p><italic>Acinetobacter</italic> spp. is increasingly recognized as an important cause of HAI, (<xref ref-type="bibr" rid="bib19">Munoz-Price and Weinstein, 2008</xref>; <xref ref-type="bibr" rid="bib24">Peleg and Hooper, 2010</xref>) and our study confirms the importance of this species as a leading cause of hospital-acquired MDR infection in a developing tropical country (<xref ref-type="bibr" rid="bib10">Hongsuwan et al., 2014</xref>; <xref ref-type="bibr" rid="bib22">Nhu et al., 2014</xref>). The high mortality observed in MDR <italic>Acinetobacter</italic> spp. bacteraemia is because treatment options are limited and those available are associated with toxicity (<xref ref-type="bibr" rid="bib8">Fishbain and Peleg, 2010</xref>). The high proportions of <italic>S. aureus, E. coli</italic> and <italic>K. pneumoniae</italic> bactaeremia being caused by MRSA and <italic>E. coli</italic> and <italic>K. pneumoniae</italic> non-susceptible to extended-spectrum cephalosporins, respectively, are consistent with previous reports from other tropical countries (<xref ref-type="bibr" rid="bib18">Moreno et al., 2006</xref>; <xref ref-type="bibr" rid="bib5">Cuellar et al., 2008</xref>; <xref ref-type="bibr" rid="bib27">Rosenthal et al., 2003</xref>). The rising proportions of community-acquired <italic>E. coli</italic> and <italic>K. pneumoniae</italic> bacteraemia being caused by <italic>E. coli</italic> and <italic>K. pneumoniae</italic> non-susceptible to extended-spectrum cephalosporins, and the rising proportion of hospital-acquired <italic>Acinetobacter</italic> bacteraemia being causing <italic>Acinetobacter</italic> non-susceptible to carbapenem suggest that the burden of AMR in Thailand is deteriorating over time.</p><p>A limitation of this study is that more complete clinical data were not available. Mortality attributable to MDR could be overestimated if MDR infection was associated with more severely ill patients in ICUs. However, our estimated attributable mortality is comparable to the previous reports. For example, our estimated mortality attributable to MDR <italic>Acinetobacter</italic> bacteraemia (40.6%) is comparable to the mortality attributable to imipenem resistant <italic>Acinetobacter</italic> bacteraemia reported by Kwon <italic>et al.</italic> in Korea (41.1%), which was adjusted by severity of illness (<xref ref-type="bibr" rid="bib13">Kwon et al., 2007</xref>; <xref ref-type="bibr" rid="bib7">Falagas and Rafailidis, 2007</xref>). In addition, data on hospitalization in other hospitals not participating in the study (for example, a smaller community hospital or a private hospital in the province) were not available, which could have resulted in a misclassification of CAB, HCAB and HAB in some cases. We also note that data on attributable mortality from different countries is difficult to compare because of the differing study designs. For example, our mortality outcome is the overall 30-day mortality, including both directly and indirectly contributed to MDR, while an EU study only considered directly attributable deaths (<xref ref-type="bibr" rid="bib6">European Centre for Disease Prevention and Control and European Medicines Agency, 2009</xref>). The p values for trends were generated by the stratification method; therefore, the analysis was not biased towards the increasing availability of the hospital data over the study period. Nonetheless, the trends could be affected by an increasing use of blood culture, changes in antimicrobial agents tested for susceptibility, and greater standardization of laboratory methodologies over time (<xref ref-type="bibr" rid="bib23">Opartkiattikul and Bejrachandra, 2002</xref>). It is likely that the burdens of MDR similar to that observed in our study are present in many secondary and tertiary hospitals in tropical LMICs, particularly where extended-spectrum cephalosporins and carbapenem are widely used. Nonetheless, resources for diagnostics, methodologies used in the laboratories, and study designs need to be carefully considered when performing a comparison between different settings.</p><p>Despite the increasing global focus on AMR in LMICs, considerable gaps remain in our understanding of the scale of the problem. We have demonstrated that the integration of information from readily available routinely collected databases can provide valuable information on the trends and mortality attributable to AMR in Thailand. The methodology used in our study could be applied to explore the burden of AMR in other LMICs where microbiological facilities and hospital admission database are available.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Study population</title><p>From 2004 to 2010, Thailand was classified as a lower-middle income country with an average income of $4782 per person per year in 2010 (<xref ref-type="bibr" rid="bib30">WorldBank, 2015</xref>). Northeast Thailand consists of 20 provinces covering 170,226 km and had an estimated population of 21.4 million in 2010. A large proportion of the population in this area lives in rural settings, with most adults engaging in agriculture with an emphasis on rice farming. Healthcare in Thailand is mainly provided by government-owned hospitals. Each province has a provincial hospital, which provides services and care to individuals within its catchment area. Additionally, provincial hospitals act as referral hospitals for smaller community hospitals for severely ill patients. All provincial hospitals receive comparable resources, which are proportional to the respective populations of the provinces. Provincial hospitals, unlike smaller community hospitals, are equipped with a microbiology laboratory capable of performing bacterial culture using standard methodologies for bacterial identification and susceptibility testing provided by the Bureau of Laboratory Quality and Standards, Ministry of Public Health (MoPH), Thailand (<xref ref-type="bibr" rid="bib23">Opartkiattikul and Bejrachandra, 2002</xref>). During the study period, antimicrobial susceptibility was determined in all study hospitals using the disc diffusion method according to Clinical and Laboratory Standards Institute (CLSI) (<xref ref-type="bibr" rid="bib20">National Committee for Clinical Laboratory Standards, 2004</xref>).</p></sec><sec id="s4-2"><title>Study design</title><p>We conducted a retrospective, multicentre surveillance study of all provincial hospitals in Northeast Thailand. From the hospitals that agreed to participate, data were collected from microbiology and hospital databases between January 2004 and December 2010. Hospital number (HN) and admission number (AN) were used as a record linkage between the two databases and to identify individuals who had repeat admissions. The death registry for Northeast Thailand was obtained from the Ministry of Interior (MoI), Thailand, and used to identify patients who were discharged from hospital but died at home shortly after, which is a common practice in Thailand (<xref ref-type="bibr" rid="bib11">Kanoksil et al., 2013</xref>; <xref ref-type="bibr" rid="bib10">Hongsuwan et al., 2014</xref>). Ethical permission for this study was obtained from the Ethical and Scientific Review Committees of the Faculty of Tropical Medicine, Mahidol University, and of the MoPH, Thailand. Written consent was given by the directors of the hospitals to use their routine hospital database for research. Consent was not sought from the patients as this was a retrospective study, and the Ethical and Scientific Review Committees approved the process.</p></sec><sec id="s4-3"><title>Data collection</title><p>The microbiology laboratory data collected included hospital number (HN), admission number (AN), specimen type, specimen date, culture result, and antibiotic susceptibility profile (antibiogram). We consulted with study sites when the results of antimicrobial susceptibility testing were unclear. Hospital admission data were collected from the routine in-patient discharge report, which is regularly completed by attending physicians and reported to the MoPH, Thailand, as part of the national morbidity and mortality reporting system. The data collected included HN, AN, national identification 13-digit number, admission date, and discharge date. Date of death was also extracted from this record. Data collected from the national death registry obtained from the MoI included the national identification 13-digit number and the date of death.</p></sec><sec id="s4-4"><title>Definitions</title><p>Bacteraemia was classified as CAB, HAB and HCAB as described previously (<xref ref-type="bibr" rid="bib11">Kanoksil et al., 2013</xref>; <xref ref-type="bibr" rid="bib10">Hongsuwan et al., 2014</xref>). Polymicrobial infection was defined in patients who had more than one species of pathogenic organisms isolated from the blood during the same episode, and was excluded from the analysis. Information on the incidence of CAB, HCAB and HAB from all pathogenic organisms has been published previously (<xref ref-type="bibr" rid="bib11">Kanoksil et al., 2013</xref>; <xref ref-type="bibr" rid="bib10">Hongsuwan et al., 2014</xref>).</p><p>The 30-day mortality of CAB and HCAB was defined as death within 30 days of the admission date. The 30-day mortality of HAB was determined on the basis of a record of death within 30 days of the positive blood culture taken as recorded in the routine hospital database or by a record of death in the national death registry. In the event that a patient had more than one episode of bacteraemia, only the first episode was included in the study.</p><p>The standard definition of MDR proposed by ECDC/CDC was used (<xref ref-type="bibr" rid="bib15">Magiorakos et al., 2012</xref>). In brief, MDR was defined as non-susceptibility to at least one agent in three or more antimicrobial categories. Additionally, methicillin-resistant <italic>Staphylococcus aureus</italic> (MRSA) were automatically described as MDR (<xref ref-type="bibr" rid="bib15">Magiorakos et al., 2012</xref>).</p></sec><sec id="s4-5"><title>Statistical analysis</title><p>Pearson’s chi-squared test and Fisher’s Exact test were used to compare categorical variables. A non-parametric test for trends was used to assess changes in prevalence of antimicrobial resistance over time stratified by hospital (using the npt_s command in STATA).</p><p>Mortality of patients with a first episode of HAB, HCAB and HAB caused by <italic>S. aureus, Enterococcus</italic> spp., <italic>E. coli, K. pneumoniae, Pseudomonas aeruginosa,</italic> and <italic>Acinetobacter</italic> spp. were evaluated in relation to MDR. We selected these organisms based on guidelines for MDR proposed by ECDC/CDC, (<xref ref-type="bibr" rid="bib15">Magiorakos et al., 2012</xref>) and the fact that <italic>E. coli</italic> and <italic>K. pneumoniae</italic> were the most common causes of bacteraemia caused by <italic>Enterobacteriaceae</italic> in our setting (<xref ref-type="bibr" rid="bib11">Kanoksil et al., 2013</xref>; <xref ref-type="bibr" rid="bib10">Hongsuwan et al., 2014</xref>). Isolates tested for less than three antimicrobial categories were excluded from the analysis because they were not applicable to ECDC/CDC standard definitions of MDR. To examine the association between MDR and mortality, we performed a multivariable logistic regression analysis adjusting for a priori selected baseline confounders. To take account of the fact that patients with CAB, HCAB, and HAB were different populations with different definitions of 30-day mortality, we applied models to each group (CAB, HCAB and HAB) separately. Multivariable logistic regression models were developed using a purposeful selection method (<xref ref-type="bibr" rid="bib3">Bursac et al., 2008</xref>). Potential confounding variables evaluated included age, gender and admission year. In the model for HAB, time to bacteraemia was also evaluated as a potential confounder because there was evidence suggesting that time to HAI was associated with mortality from HAI (<xref ref-type="bibr" rid="bib17">Moine et al., 2002</xref>; <xref ref-type="bibr" rid="bib21">Nguile-Makao et al., 2010</xref>). Time to bacteremia was defined as the duration between hospital admission and the date positive blood culture was taken. All models were stratified by hospital.</p><p>The mortality attributable to MDR was calculated using adjusted odds ratios (aORs) estimated by the final multivariable logistic regression models. If X was the observed mortality in patients with MDR infection, the estimated odds of mortality if they were infected with non-MDR organisms (O) would be (1/aOR)*(X/(1-X)). Assuming that excess mortality was due to MDR, then the mortality attributable to MDR would be the absolute difference between mortality in patients with MDR infection (X) and the predicted mortality if they were infected with non-MDR organisms (O/(1+O)), which would be X – (O/(1+O)) (<xref ref-type="bibr" rid="bib2">Benichou, 2001</xref>; <xref ref-type="bibr" rid="bib9">Greenland and Robins, 1988</xref>). Heterogeneity between different organisms within each group of patients (CAB, HCAB, and HAB) was assessed using the chi-squared test, and the percentage of variation due to heterogeneity (I-square) was calculated.</p><p>The number of deaths attributable to MDR in Thailand was determined using the methodology described previously (<xref ref-type="bibr" rid="bib6">European Centre for Disease Prevention and Control and European Medicines Agency, 2009</xref>). Data used included our estimated mortality attributable to MDR bacteraemia and cumulative incidence of HAI bacteraemia, lower respiratory track infection (LRTI), urinary tract infection (UTI), skin and soft tissue infection (SSTI), and other sites of infection caused by MDR <italic>S. aureus, E. coli, K. pneumoniae, P. aeruginosa,</italic> and <italic>Acinetobacter</italic> spp. in Thailand in 2010, which have been described previously (<xref ref-type="bibr" rid="bib25">Pumart et al., 2012</xref>). Death attributable to MDR <italic>Enterococcus</italic> spp. was not included as the cumulative incidence of MDR <italic>Enterococcus</italic> infection in Thailand was not available (<xref ref-type="bibr" rid="bib25">Pumart et al., 2012</xref>). Attributable mortality by site of infection (LRTI, UTI, SSTI and other site) was estimated by applying correction factors corresponding to the relative mortality from infections of those sites compared to bacteraemia (<xref ref-type="bibr" rid="bib16">Martone et al., 1998</xref>). All analyses were performed using STATA version 14.0 (StataCorp LP, College station, Texas, USA).</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We gratefully acknowledge the Bacterial Infection in North East Thailand (BINET) network for providing microbiological and hospital admission data. BINET are comprised of Chalavit Limpavithayakula, Chatchawan Namsorn, Chadaporn Paungmala (Amnat Chareon hospital), Chan Tantiwaraporn, Somsak Kitisriworapun, Kanyapak Panjaiya, Kridsada Sirichaisit (Bueng Kan hospital), Chalit Thongprayoon, Somchai Jittai, Rattana Jirajaruporn (Burirum hospital), Sompong Charoenwat, Some Prasarn, Wiset Phosawang, Peeraphorn Lamworaphong (Chaiyaphum hospital), Pramoth Boonjian, Pattarawadee Wongmeema, Sunthorn Thongbai (Loei hospital), Sunthorn Yontrakul, Piyalak Siritaratiwat, Supanne Pisuttimarn (Mahasarakham hospital), Udom Pedphuwadee (Mukdahan hospital), Somkid Suriyalert, Pichai Thongtaradol, Somsri Viriyaphun (Nakhon Phanom hospital), Kittisak Danwiboon, Kanjana Kehatan, Wannakorn Dechnorasing (Nongkhai hospital), Narong Uen- trakul (Roi Et hospital), Somsak Chaosirikul, Anek Jaddee, Soontorn Romaneeyapech (Sisaket hospital), Thongchai Triwiboonwanich, Saowarat Deekae, Vorathep Wuttisil (Surin hospital), Pramot Srisamang, Nittaya Teerawattanasook (Ubon Ratchathani hospital), Pichart Dolchalermyuttana, Yaowalau Lootrakul, Sayrung Sripavatakul (Udon Thani hospital), Charan Thongthap, Pongsathorn Siripoulsak, Chainakhon Kaewluang (Yasothon hospital). We thank the Ministry of Interior, Thailand, for national death registry data. We thank Mayura Malasit and Jittana Suwannapruk for their administrative support. We gratefully acknowledge the support provided by staff at the Mahidol-Oxford Tropical Medicine Research Unit and at all participating hospitals. We thank Prapass Wanapinij, Kraiwuth Sriporamanont, Mongkol Fungprasertkul and Dean Sherwood for computational support. The authors thank NJ White for comments on the final draft.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>CL, Conception and design, Analysis and interpretation of data, Drafting or revising the article</p></fn><fn fn-type="con" id="con2"><p>ET, Conception and design, Analysis and interpretation of data, Drafting or revising the article</p></fn><fn fn-type="con" id="con3"><p>MH, Acquisition of data, Analysis and interpretation of data</p></fn><fn fn-type="con" id="con4"><p>VW, Conception and design, Analysis and interpretation of data, Drafting or revising the article</p></fn><fn fn-type="con" id="con5"><p>VT, Analysis and interpretation of data, Drafting or revising the article</p></fn><fn fn-type="con" id="con6"><p>SH, Analysis and interpretation of data, Drafting or revising the article</p></fn><fn fn-type="con" id="con7"><p>NPJD, Conception and design, Drafting or revising the article</p></fn><fn fn-type="con" id="con8"><p>SJP, Conception and design, Analysis and interpretation of data, Drafting or revising the article</p></fn><fn fn-type="con" id="con9"><p>DL, Conception and design, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="SD2-data"><object-id pub-id-type="doi">10.7554/eLife.18082.019</object-id><label>Supplementary file 1.</label><caption><title>Factors associated with 30-day mortality of bacteraemia patients.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.18082.019">http://dx.doi.org/10.7554/eLife.18082.019</ext-link></p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-18082-supp1-v2.docx"/></supplementary-material><supplementary-material id="SD3-data"><object-id pub-id-type="doi">10.7554/eLife.18082.020</object-id><label>Supplementary file 2.</label><caption><title>Parameters used to estimate mortality attributable to multidrug-resistance in Thailand.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.18082.020">http://dx.doi.org/10.7554/eLife.18082.020</ext-link></p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-18082-supp2-v2.docx"/></supplementary-material></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ansari</surname><given-names>S</given-names></name><name><surname>Nepal</surname><given-names>HP</given-names></name><name><surname>Gautam</surname><given-names>R</given-names></name><name><surname>Shrestha</surname><given-names>S</given-names></name><name><surname>Neopane</surname><given-names>P</given-names></name><name><surname>Gurung</surname><given-names>G</given-names></name><name><surname>Chapagain</surname><given-names>ML</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Community acquired multi-drug resistant clinical isolates of Escherichia coli in a tertiary care center of Nepal</article-title><source>Antimicrobial Resistance and Infection Control</source><volume>4</volume><fpage>15</fpage><pub-id pub-id-type="doi">10.1186/s13756-015-0059-2</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benichou</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>A review of adjusted estimators of attributable risk</article-title><source>Statistical Methods in Medical Research</source><volume>10</volume><fpage>195</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1191/096228001680195157</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bursac</surname><given-names>Z</given-names></name><name><surname>Gauss</surname><given-names>CH</given-names></name><name><surname>Williams</surname><given-names>DK</given-names></name><name><surname>Hosmer</surname><given-names>DW</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Purposeful selection of variables in logistic regression</article-title><source>Source Code for Biology and Medicine</source><volume>3</volume><fpage>17</fpage><pub-id pub-id-type="doi">10.1186/1751-0473-3-17</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="web"><person-group person-group-type="author"><collab>Center for Disease Controls and Prevention, U.S. Department of Health and Human Services</collab></person-group><year iso-8601-date="2013">2013</year><article-title>Antibiotic resistance threats in the United States, 2013</article-title><uri xlink:href="http://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf">http://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf</uri></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuellar</surname><given-names>LE</given-names></name><name><surname>Fernandez-Maldonado</surname><given-names>E</given-names></name><name><surname>Rosenthal</surname><given-names>VD</given-names></name><name><surname>Castaneda-Sabogal</surname><given-names>A</given-names></name><name><surname>Rosales</surname><given-names>R</given-names></name><name><surname>Mayorga-Espichan</surname><given-names>MJ</given-names></name><name><surname>Camacho-Cosavalente</surname><given-names>LA</given-names></name><name><surname>Castillo-Bravo</surname><given-names>LI</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Device-associated infection rates and mortality in intensive care units of Peruvian hospitals: findings of the International Nosocomial Infection Control Consortium</article-title><source>Revista Panamericana De Salud Pública</source><volume>24</volume><fpage>16</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1590/S1020-49892008000700002</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="web"><person-group person-group-type="author"><collab>European Centre for Disease Prevention and Control and European Medicines Agency</collab></person-group><year iso-8601-date="2009">2009</year><article-title>ECDC/EMEA joint technical report the bacterial challenge: Time to react 2009</article-title><uri xlink:href="http://ecdc.europa.eu/en/publications/Publications/0909_TER_The_Bacterial_Challenge_Time_to_React.pdf">http://ecdc.europa.eu/en/publications/Publications/0909_TER_The_Bacterial_Challenge_Time_to_React.pdf</uri></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falagas</surname><given-names>ME</given-names></name><name><surname>Rafailidis</surname><given-names>PI</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Attributable mortality of <italic>Acinetobacter</italic> baumannii: no longer a controversial issue</article-title><source>Critical Care</source><volume>11</volume><fpage>134</fpage><pub-id pub-id-type="doi">10.1186/cc5911</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fishbain</surname><given-names>J</given-names></name><name><surname>Peleg</surname><given-names>AY</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Treatment of <italic>Acinetobacter</italic> infections</article-title><source>Clinical Infectious Diseases</source><volume>51</volume><fpage>79</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1086/653120</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenland</surname><given-names>S</given-names></name><name><surname>Robins</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="1988">1988</year><article-title>Conceptual problems in the definition and interpretation of attributable fractions</article-title><source>American Journal of Epidemiology</source><volume>128</volume><fpage>1185</fpage><lpage>1197</lpage></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hongsuwan</surname><given-names>M</given-names></name><name><surname>Srisamang</surname><given-names>P</given-names></name><name><surname>Kanoksil</surname><given-names>M</given-names></name><name><surname>Luangasanatip</surname><given-names>N</given-names></name><name><surname>Jatapai</surname><given-names>A</given-names></name><name><surname>Day</surname><given-names>NP</given-names></name><name><surname>Peacock</surname><given-names>SJ</given-names></name><name><surname>Cooper</surname><given-names>BS</given-names></name><name><surname>Limmathurotsakul</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Increasing incidence of hospital-acquired and healthcare-associated bacteremia in northeast Thailand: a multicenter surveillance study</article-title><source>PLoS ONE</source><volume>9</volume><elocation-id>e109324</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0109324</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanoksil</surname><given-names>M</given-names></name><name><surname>Jatapai</surname><given-names>A</given-names></name><name><surname>Peacock</surname><given-names>SJ</given-names></name><name><surname>Limmathurotsakul</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Epidemiology, microbiology and mortality associated with community-acquired bacteremia in northeast Thailand: a multicenter surveillance study</article-title><source>PLoS ONE</source><volume>8</volume><elocation-id>e54714</elocation-id><pub-id pub-id-type="doi">10.1371/annotation/e199ebcc-0bc1-4be1-ad91-ad2a8c0c9382</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kayange</surname><given-names>N</given-names></name><name><surname>Kamugisha</surname><given-names>E</given-names></name><name><surname>Mwizamholya</surname><given-names>DL</given-names></name><name><surname>Jeremiah</surname><given-names>S</given-names></name><name><surname>Mshana</surname><given-names>SE</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Predictors of positive blood culture and deaths among neonates with suspected neonatal sepsis in a tertiary hospital, Mwanza-Tanzania</article-title><source>BMC Pediatrics</source><volume>10</volume><elocation-id>39</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2431-10-39</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwon</surname><given-names>KT</given-names></name><name><surname>Oh</surname><given-names>WS</given-names></name><name><surname>Song</surname><given-names>JH</given-names></name><name><surname>Chang</surname><given-names>HH</given-names></name><name><surname>Jung</surname><given-names>SI</given-names></name><name><surname>Kim</surname><given-names>SW</given-names></name><name><surname>Ryu</surname><given-names>SY</given-names></name><name><surname>Heo</surname><given-names>ST</given-names></name><name><surname>Jung</surname><given-names>DS</given-names></name><name><surname>Rhee</surname><given-names>JY</given-names></name><name><surname>Shin</surname><given-names>SY</given-names></name><name><surname>Ko</surname><given-names>KS</given-names></name><name><surname>Peck</surname><given-names>KR</given-names></name><name><surname>Lee</surname><given-names>NY</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Impact of imipenem resistance on mortality in patients with <italic>Acinetobacter</italic> bacteraemia</article-title><source>Journal of Antimicrobial Chemotherapy</source><volume>59</volume><fpage>525</fpage><lpage>530</lpage><pub-id pub-id-type="doi">10.1093/jac/dkl499</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laxminarayan</surname><given-names>R</given-names></name><name><surname>Duse</surname><given-names>A</given-names></name><name><surname>Wattal</surname><given-names>C</given-names></name><name><surname>Zaidi</surname><given-names>AK</given-names></name><name><surname>Wertheim</surname><given-names>HF</given-names></name><name><surname>Sumpradit</surname><given-names>N</given-names></name><name><surname>Vlieghe</surname><given-names>E</given-names></name><name><surname>Hara</surname><given-names>GL</given-names></name><name><surname>Gould</surname><given-names>IM</given-names></name><name><surname>Goossens</surname><given-names>H</given-names></name><name><surname>Greko</surname><given-names>C</given-names></name><name><surname>So</surname><given-names>AD</given-names></name><name><surname>Bigdeli</surname><given-names>M</given-names></name><name><surname>Tomson</surname><given-names>G</given-names></name><name><surname>Woodhouse</surname><given-names>W</given-names></name><name><surname>Ombaka</surname><given-names>E</given-names></name><name><surname>Peralta</surname><given-names>AQ</given-names></name><name><surname>Qamar</surname><given-names>FN</given-names></name><name><surname>Mir</surname><given-names>F</given-names></name><name><surname>Kariuki</surname><given-names>S</given-names></name><name><surname>Bhutta</surname><given-names>ZA</given-names></name><name><surname>Coates</surname><given-names>A</given-names></name><name><surname>Bergstrom</surname><given-names>R</given-names></name><name><surname>Wright</surname><given-names>GD</given-names></name><name><surname>Brown</surname><given-names>ED</given-names></name><name><surname>Cars</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Antibiotic resistance-the need for global solutions</article-title><source>The Lancet Infectious Diseases</source><volume>13</volume><fpage>1057</fpage><lpage>1098</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(13)70318-9</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magiorakos</surname><given-names>AP</given-names></name><name><surname>Srinivasan</surname><given-names>A</given-names></name><name><surname>Carey</surname><given-names>RB</given-names></name><name><surname>Carmeli</surname><given-names>Y</given-names></name><name><surname>Falagas</surname><given-names>ME</given-names></name><name><surname>Giske</surname><given-names>CG</given-names></name><name><surname>Harbarth</surname><given-names>S</given-names></name><name><surname>Hindler</surname><given-names>JF</given-names></name><name><surname>Kahlmeter</surname><given-names>G</given-names></name><name><surname>Olsson-Liljequist</surname><given-names>B</given-names></name><name><surname>Paterson</surname><given-names>DL</given-names></name><name><surname>Rice</surname><given-names>LB</given-names></name><name><surname>Stelling</surname><given-names>J</given-names></name><name><surname>Struelens</surname><given-names>MJ</given-names></name><name><surname>Vatopoulos</surname><given-names>A</given-names></name><name><surname>Weber</surname><given-names>JT</given-names></name><name><surname>Monnet</surname><given-names>DL</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance</article-title><source>Clinical Microbiology and Infection</source><volume>18</volume><fpage>268</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1111/j.1469-0691.2011.03570.x</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Martone</surname><given-names>WJ</given-names></name><name><surname>Jarvis</surname><given-names>WR</given-names></name><name><surname>Edwards</surname><given-names>JR</given-names></name><name><surname>Culver</surname><given-names>DH</given-names></name><name><surname>Haley</surname><given-names>RW</given-names></name></person-group><year iso-8601-date="1998">1998</year><chapter-title>Incidence and nature of endemic and epidemic nosocomial infections</chapter-title><person-group person-group-type="editor"><name><surname>Bennett</surname> <given-names>J. V</given-names></name><name><surname>Brachman</surname> <given-names>P. S</given-names></name></person-group><source>Hospital Infections</source><edition>4th ed</edition><publisher-loc>Philadelphia, PA, USA</publisher-loc><publisher-name>Lippincott-Raven</publisher-name><fpage>461</fpage><lpage>476</lpage></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moine</surname><given-names>P</given-names></name><name><surname>Timsit</surname><given-names>JF</given-names></name><name><surname>De Lassence</surname><given-names>A</given-names></name><name><surname>Troché</surname><given-names>G</given-names></name><name><surname>Fosse</surname><given-names>JP</given-names></name><name><surname>Alberti</surname><given-names>C</given-names></name><name><surname>Cohen</surname><given-names>Y</given-names></name><collab>OUTCOMEREA study group</collab></person-group><year iso-8601-date="2002">2002</year><article-title>Mortality associated with late-onset pneumonia in the intensive care unit: results of a multi-center cohort study</article-title><source>Intensive Care Medicine</source><volume>28</volume><fpage>154</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1007/s00134-001-1172-7</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moreno</surname><given-names>CA</given-names></name><name><surname>Rosenthal</surname><given-names>VD</given-names></name><name><surname>Olarte</surname><given-names>N</given-names></name><name><surname>Gomez</surname><given-names>WV</given-names></name><name><surname>Sussmann</surname><given-names>O</given-names></name><name><surname>Agudelo</surname><given-names>JG</given-names></name><name><surname>Rojas</surname><given-names>C</given-names></name><name><surname>Osorio</surname><given-names>L</given-names></name><name><surname>Linares</surname><given-names>C</given-names></name><name><surname>Valderrama</surname><given-names>A</given-names></name><name><surname>Mercado</surname><given-names>PG</given-names></name><name><surname>Bernate</surname><given-names>PH</given-names></name><name><surname>Vergara</surname><given-names>GR</given-names></name><name><surname>Pertuz</surname><given-names>AM</given-names></name><name><surname>Mojica</surname><given-names>BE</given-names></name><name><surname>Navarrete</surname><given-names>MP</given-names></name><name><surname>Romero</surname><given-names>AS</given-names></name><name><surname>Henriquez</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Device-associated infection rate and mortality in intensive care units of 9 Colombian hospitals: findings of the International Nosocomial Infection Control Consortium</article-title><source>Infection Control and Hospital Epidemiology</source><volume>27</volume><fpage>349</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.1086/503341</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munoz-Price</surname><given-names>LS</given-names></name><name><surname>Weinstein</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title><italic>Acinetobacter</italic> infection</article-title><source>New England Journal of Medicine</source><volume>358</volume><fpage>1271</fpage><lpage>1281</lpage><pub-id pub-id-type="doi">10.1056/NEJMra070741</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="book"><person-group person-group-type="author"><collab>National Committee for Clinical Laboratory Standards</collab></person-group><year iso-8601-date="2004">2004</year><chapter-title>Performance Standards for Antimicrobial Disk Susceptibility Tests</chapter-title><source>NCCLS Document M100-514</source><publisher-loc>Wayne Pa</publisher-loc><publisher-name>National Committee for Clinical Laboratory Standards</publisher-name></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguile-Makao</surname><given-names>M</given-names></name><name><surname>Zahar</surname><given-names>JR</given-names></name><name><surname>Français</surname><given-names>A</given-names></name><name><surname>Tabah</surname><given-names>A</given-names></name><name><surname>Garrouste-Orgeas</surname><given-names>M</given-names></name><name><surname>Allaouchiche</surname><given-names>B</given-names></name><name><surname>Goldgran-Toledano</surname><given-names>D</given-names></name><name><surname>Azoulay</surname><given-names>E</given-names></name><name><surname>Adrie</surname><given-names>C</given-names></name><name><surname>Jamali</surname><given-names>S</given-names></name><name><surname>Clec'h</surname><given-names>C</given-names></name><name><surname>Souweine</surname><given-names>B</given-names></name><name><surname>Timsit</surname><given-names>JF</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Attributable mortality of ventilator-associated pneumonia: respective impact of main characteristics at ICU admission and VAP onset using conditional logistic regression and multi-state models</article-title><source>Intensive Care Medicine</source><volume>36</volume><fpage>781</fpage><lpage>789</lpage><pub-id pub-id-type="doi">10.1007/s00134-010-1824-6</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nhu</surname><given-names>NT</given-names></name><name><surname>Lan</surname><given-names>NP</given-names></name><name><surname>Campbell</surname><given-names>JI</given-names></name><name><surname>Parry</surname><given-names>CM</given-names></name><name><surname>Thompson</surname><given-names>C</given-names></name><name><surname>Tuyen</surname><given-names>HT</given-names></name><name><surname>Hoang</surname><given-names>NV</given-names></name><name><surname>Tam</surname><given-names>PT</given-names></name><name><surname>Le</surname><given-names>VM</given-names></name><name><surname>Nga</surname><given-names>TV</given-names></name><name><surname>Nhu</surname><given-names>TH</given-names></name><name><surname>Van Minh</surname><given-names>P</given-names></name><name><surname>Nga</surname><given-names>NT</given-names></name><name><surname>Thuy</surname><given-names>CT</given-names></name><name><surname>Dung</surname><given-names>le T</given-names></name><name><surname>Yen</surname><given-names>NT</given-names></name><name><surname>Van Hao</surname><given-names>N</given-names></name><name><surname>Loan</surname><given-names>HT</given-names></name><name><surname>Yen</surname><given-names>LM</given-names></name><name><surname>Nghia</surname><given-names>HD</given-names></name><name><surname>Hien</surname><given-names>TT</given-names></name><name><surname>Thwaites</surname><given-names>L</given-names></name><name><surname>Thwaites</surname><given-names>G</given-names></name><name><surname>Chau</surname><given-names>NV</given-names></name><name><surname>Baker</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Emergence of carbapenem-resistant <italic>Acinetobacter</italic> baumannii as the major cause of ventilator-associated pneumonia in intensive care unit patients at an infectious disease hospital in southern Vietnam</article-title><source>Journal of Medical Microbiology</source><volume>63</volume><fpage>1386</fpage><lpage>1394</lpage><pub-id pub-id-type="doi">10.1099/jmm.0.076646-0</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Opartkiattikul</surname><given-names>N</given-names></name><name><surname>Bejrachandra</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>The external quality assessment schemes in Thailand</article-title><source>Rinsho Byori. the Japanese Journal of Clinical Pathology</source><volume>50</volume><fpage>121</fpage><lpage>125</lpage></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peleg</surname><given-names>AY</given-names></name><name><surname>Hooper</surname><given-names>DC</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Hospital-acquired infections due to gram-negative bacteria</article-title><source>New England Journal of Medicine</source><volume>362</volume><fpage>1804</fpage><lpage>1813</lpage><pub-id pub-id-type="doi">10.1056/NEJMra0904124</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pumart</surname><given-names>P</given-names></name><name><surname>Phodha</surname><given-names>T</given-names></name><name><surname>Thamlikitkul</surname><given-names>V</given-names></name><name><surname>Riewpaiboon</surname><given-names>A</given-names></name><name><surname>Prakongsai</surname><given-names>P</given-names></name><name><surname>Limwattananon</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Health and economic impacts of antimicrobial resistance in Thailand</article-title><source>Journal Health Services Research Policy</source><volume>9</volume><fpage>352</fpage><lpage>360</lpage></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>RR</given-names></name><name><surname>Hota</surname><given-names>B</given-names></name><name><surname>Ahmad</surname><given-names>I</given-names></name><name><surname>Scott</surname><given-names>RD</given-names></name><name><surname>Foster</surname><given-names>SD</given-names></name><name><surname>Abbasi</surname><given-names>F</given-names></name><name><surname>Schabowski</surname><given-names>S</given-names></name><name><surname>Kampe</surname><given-names>LM</given-names></name><name><surname>Ciavarella</surname><given-names>GG</given-names></name><name><surname>Supino</surname><given-names>M</given-names></name><name><surname>Naples</surname><given-names>J</given-names></name><name><surname>Cordell</surname><given-names>R</given-names></name><name><surname>Levy</surname><given-names>SB</given-names></name><name><surname>Weinstein</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship</article-title><source>Clinical Infectious Diseases</source><volume>49</volume><fpage>1175</fpage><lpage>1184</lpage><pub-id pub-id-type="doi">10.1086/605630</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenthal</surname><given-names>VD</given-names></name><name><surname>Guzman</surname><given-names>S</given-names></name><name><surname>Orellano</surname><given-names>PW</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Nosocomial infections in medical-surgical intensive care units in Argentina: attributable mortality and length of stay</article-title><source>American Journal of Infection Control</source><volume>31</volume><fpage>291</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1067/mic.2003.1</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenthal</surname><given-names>VD</given-names></name><name><surname>Maki</surname><given-names>DG</given-names></name><name><surname>Mehta</surname><given-names>Y</given-names></name><name><surname>Leblebicioglu</surname><given-names>H</given-names></name><name><surname>Memish</surname><given-names>ZA</given-names></name><name><surname>Al-Mousa</surname><given-names>HH</given-names></name><name><surname>Balkhy</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>B</given-names></name><name><surname>Alvarez-Moreno</surname><given-names>C</given-names></name><name><surname>Medeiros</surname><given-names>EA</given-names></name><name><surname>Apisarnthanarak</surname><given-names>A</given-names></name><name><surname>Raka</surname><given-names>L</given-names></name><name><surname>Cuellar</surname><given-names>LE</given-names></name><name><surname>Ahmed</surname><given-names>A</given-names></name><name><surname>Navoa-Ng</surname><given-names>JA</given-names></name><name><surname>El-Kholy</surname><given-names>AA</given-names></name><name><surname>Kanj</surname><given-names>SS</given-names></name><name><surname>Bat-Erdene</surname><given-names>I</given-names></name><name><surname>Duszynska</surname><given-names>W</given-names></name><name><surname>Van Truong</surname><given-names>N</given-names></name><name><surname>Pazmino</surname><given-names>LN</given-names></name><name><surname>See-Lum</surname><given-names>LC</given-names></name><name><surname>Fernández-Hidalgo</surname><given-names>R</given-names></name><name><surname>Di-Silvestre</surname><given-names>G</given-names></name><name><surname>Zand</surname><given-names>F</given-names></name><name><surname>Hlinkova</surname><given-names>S</given-names></name><name><surname>Belskiy</surname><given-names>V</given-names></name><name><surname>Al-Rahma</surname><given-names>H</given-names></name><name><surname>Luque-Torres</surname><given-names>MT</given-names></name><name><surname>Bayraktar</surname><given-names>N</given-names></name><name><surname>Mitrev</surname><given-names>Z</given-names></name><name><surname>Gurskis</surname><given-names>V</given-names></name><name><surname>Fisher</surname><given-names>D</given-names></name><name><surname>Abu-Khader</surname><given-names>IB</given-names></name><name><surname>Berechid</surname><given-names>K</given-names></name><name><surname>Rodríguez-Sánchez</surname><given-names>A</given-names></name><name><surname>Horhat</surname><given-names>FG</given-names></name><name><surname>Requejo-Pino</surname><given-names>O</given-names></name><name><surname>Hadjieva</surname><given-names>N</given-names></name><name><surname>Ben-Jaballah</surname><given-names>N</given-names></name><name><surname>García-Mayorca</surname><given-names>E</given-names></name><name><surname>Kushner-Dávalos</surname><given-names>L</given-names></name><name><surname>Pasic</surname><given-names>S</given-names></name><name><surname>Pedrozo-Ortiz</surname><given-names>LE</given-names></name><name><surname>Apostolopoulou</surname><given-names>E</given-names></name><name><surname>Mejía</surname><given-names>N</given-names></name><name><surname>Gamar-Elanbya</surname><given-names>MO</given-names></name><name><surname>Jayatilleke</surname><given-names>K</given-names></name><name><surname>de Lourdes-Dueñas</surname><given-names>M</given-names></name><name><surname>Aguirre-Avalos</surname><given-names>G</given-names></name><collab>International Nosocomial Infection Control Consortium</collab></person-group><year iso-8601-date="2014">2014</year><article-title>International Nosocomial Infection Control Consortium (INICC) report, data summary of 43 countries for 2007-2012. Device-associated module</article-title><source>American Journal of Infection Control</source><volume>42</volume><fpage>942</fpage><lpage>956</lpage><pub-id pub-id-type="doi">10.1016/j.ajic.2014.05.029</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="web"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><year iso-8601-date="2014">2014</year><article-title>Antimicrobial resistance: global report on surveillance</article-title><uri xlink:href="http://apps.who.int/iris/bitstream/10665/112642/1/9789241564748_eng.pdf?ua=1">http://apps.who.int/iris/bitstream/10665/112642/1/9789241564748_eng.pdf?ua=1</uri></element-citation></ref><ref id="bib30"><element-citation publication-type="web"><person-group person-group-type="author"><collab>WorldBank</collab></person-group><year iso-8601-date="2015">2015</year><article-title>Thailand Overview</article-title><uri xlink:href="http://www.worldbank.org/en/country/thailand/overview">http://www.worldbank.org/en/country/thailand/overview</uri></element-citation></ref></ref-list></back><sub-article article-type="article-commentary" id="SA1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.18082.021</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Abdool Karim</surname><given-names>Quarraisha</given-names></name><role>Reviewing editor</role><aff id="aff9"><institution>University of KwaZulu Natal</institution>, <country>South Africa</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.</p></boxed-text><p>Thank you for submitting your article &quot;Epidemiology and Burden of Multidrug-resistant Bacterial Infection in a Developing Country&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors and the evaluation has been overseen by Prabhat Jha as the Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>Summary:</p><p>This manuscript makes an important contribution on mortality from multidrug-resistant (MDR) bacterial infection in low- and middle-income countries (LMIC). Limited mortality data from MDR bacterial infection exists in these settings. The lack of antimicrobial stewardship and poor, if any, over-the-counter control is a great concern in the face of the global health threat of multidrug resistance. Although retrospective, this is a well designed study including not only laboratory data but also some clinical data (admission and death registry) covering a large number of hospitals over 7 years.</p><p>Essential revisions:</p><p>1) The data covers the period from 2004 onwards, with different hospitals starting records at different times. It seems that <xref ref-type="table" rid="tbl1">tables 1</xref>–<xref ref-type="table" rid="tbl4">4</xref> have simply aggregated these results over time, but the authors should comment on how trends in data availability might affect the results. E.g. will increasing availability favour statistical significance amongst the results that were collected in later years? Were there differences over time either because of enhanced data collection or diagnostics? If there were no apparent trends in percent-MDR over this period, it would be helpful to show as supporting information (to illustrate that the overall epidemiology might be reasonably stable).</p><p>2) How generalizable are the sampled hospitals? Are they comparable in size, populations, and resources? Are there inter-hospital movement of participants? How common is this and how does this impact findings?</p><p>3) Expressing the estimated number of deaths in HAI attributable to MDR bacteria in percentage (in brackets after the absolute numbers) would read better.</p><p>4) There needs to be more clarification around the precise denominators being used, for the results. In particular:</p><p>a) The wording 'percentage of MDR', used throughout the manuscript, is pretty confusing – it suggests the proportion of all MDR cases (including in the community) that cause CAB, etc. This can't be possible – Instead it seems that the authors are referring to the inverse: the proportion of CAB being caused by MDR.</p><p>b) However, even this needs more clarification: as the denominators in <xref ref-type="table" rid="tbl1">Table 1</xref> are not the same down each column, it seems what the authors are referring to is the proportion of (e.g.) CAB caused by a particular pathogen, that are caused by MDR variants of that pathogen.</p><p>c) If this correct, the language should be adjusted throughout the manuscript, to make this denominator very clear – suggest something like: &quot;Of CAB, HCAB and HAB caused by <italic>S. aureus</italic>, the percentage being caused by MDR <italic>S. aureus</italic> were…&quot;, and removing references to &quot;The proportion of MDR&quot; throughout.</p><p>5) When comparisons are drawn with other settings take into account differences in setting, resources, study design, and other characteristics that may introduce bias and preclude a direct comparison.</p></body></sub-article><sub-article article-type="reply" id="SA2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.18082.022</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><p><italic>Essential revisions:</italic></p><p><italic>1) The data covers the period from 2004 onwards, with different hospitals starting records at different times. It seems that <xref ref-type="table" rid="tbl1">tables 1</xref>–<xref ref-type="table" rid="tbl4">4</xref> have simply aggregated these results over time, but the authors should comment on how trends in data availability might affect the results. E.g. will increasing availability favour statistical significance amongst the results that were collected in later years? Were there differences over time either because of enhanced data collection or diagnostics?</italic></p><p>The following sentence has been added in the Discussion section for clarity, “The p values for trends were generated by the stratification method; therefore, the analysis was not biased towards the increasing availability of the hospital data over the study period. Nonetheless, the trends could be affected by an increasing use of blood culture, changes in antimicrobial agents tested for susceptibility, and greater standardization of laboratory methodologies over time.”</p><p><italic>If there were no apparent trends in percent-MDR over this period, it would be helpful to show as supporting information (to illustrate that the overall epidemiology might be reasonably stable).</italic></p><p>Figures were added as suggested.</p><p><italic>2) How generalizable are the sampled hospitals? Are they comparable in size, populations, and resources? Are there inter-hospital movement of participants? How common is this and how does this impact findings?</italic></p><p>The following sentence has been added in the Discussion section for clarity, “It is likely that burdens of MDR similar to that observed in our study are present in many secondary and tertiary hospitals in tropical LMICs, particularly where extended-spectrum cephalosporins and carbapenem are widely used. Nonetheless, resources for diagnostics, methodologies used in the laboratories, and study designs need to be carefully considered when performing a comparison between different settings.”</p><p><italic>3) Expressing the estimated number of deaths in HAI attributable to MDR bacteria in percentage (in brackets after the absolute numbers) would read better.</italic></p><p>The percentage in brackets, “(43%)”, has been added as suggested.</p><p><italic>4) There needs to be more clarification around the precise denominators being used, for the results. In particular:</italic> </p><p><italic>a) The wording 'percentage of MDR', used throughout the manuscript, is pretty confusing – it suggests the proportion of all MDR cases (including in the community) that cause CAB, etc. This can't be possible – Instead it seems that the authors are referring to the inverse: the proportion of CAB being caused by MDR.</italic> </p><p><italic>b) However, even this needs more clarification: as the denominators in <xref ref-type="table" rid="tbl1">Table 1</xref> are not the same down each column, it seems what the authors are referring to is the proportion of (e.g.) CAB caused by a particular pathogen, that are caused by MDR variants of that pathogen.</italic> </p><p><italic>c) If this correct, the language should be adjusted throughout the manuscript, to make this denominator very clear – suggest something like: &quot;Of CAB, HCAB and HAB caused by S. aureus, the percentage being caused by MDR S. aureus were…&quot;, and removing references to &quot;The proportion of MDR&quot; throughout.</italic></p><p>The reviewers are correct; it is actually the proportion of CAB being caused by MDR variants of that pathogen. We have carefully edited this in the manuscript thoroughly as suggested.</p><p><italic>5) When comparisons are drawn with other settings take into account differences in setting, resources, study design, and other characteristics that may introduce bias and preclude a direct comparison.</italic></p><p>The following sentence has been added in the Discussion section for clarity, “Nonetheless, resources for diagnostics, methodologies used in the laboratories, and study designs need to be carefully considered when performing a comparison between different settings.”</p></body></sub-article></article>